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Yersinia pseudotuberculosis Membrane Vesicles Deliver 
Virulence Factors into Host Cells In vitro 
Abstract  
Yersinia pseudotuberculosis is a Gram-negative pathogenic bacterium that is believed to be an 
evolutionary ancestor of Yersinia pestis, a deadly pathogen causing bubonic plague. As a pathogen, Y. 
pseudotuberculosis causes a foodborne disease in humans and zoonotic infections in a variety of animal 
hosts, both wild and domestic. It is known that Yersinia pseudotuberculosis delivers various virulence 
factors into the host cells via type III secretion system (TTSS) during infection. Recent studies related 
to pathogenic bacteria showed most pathogenic bacteria uses an alternative mode of the delivery vehicle 
called membrane vesicles (MVs) in addition to their secretion systems. The current study focused on 
Yersinia pseudotuberculosis membrane vesicles and their impact on mammalian host cell in vitro. 
Transmission electron and super resolution microscopy analysis revealed 24 hours grown Y. 
pseudotuberculosis produced MVs. Further proteomic analysis by LC-MS/MS identified 887 proteins 
associated with membrane vesicles. MVs contained some secreted bacterial proteins, including 60kDa 
chaperonin (GroEL), Attachment invasion locus proteins (AilA), urease, etc.  Based on subcellular 
localization predictions, MVs were found to be a double membrane structure. Further studies on human 
airways epithelial cell NuLi1 revealed purified MVs induced morphological changes and were shown 
to be cytotoxic as they were internalized into the cells successfully delivering 60 kDa Chaperonin and 
cytotoxic necrotizing factor (CNFy).  When purified MVs were tested on murine macrophage, RAW 
264.7 cells severer actin rearrangement could be observed within 3 hours. Significant loss in raw cell 
viability could be observed after 48 hours in a dose dependent manner as determined by MTT assay 
while confocal microscopy revealed giant cell multinucleated phenotype due to MVs exposure. Flow 
cytometric analysis confirmed that apoptosis is not a major event in cytotoxicity with only 2% cells 
found to be apoptotic. Furthermore, MVs induced high levels of TNF-α in raw cells. Finally, as 
cytotoxic necrotizing factor toxin (CNFy) is one of the crucial virulence factor allied with Yersinia 
pseudotuberculosis YPIII (+), we also tried to characterize this CNFy in detail in this study. Some early 
proteomics study confirmed that there was some signature post translational modification (PTM) of the 
Y. pseudotuberculosis CNFy protein. For further confirmation, we cloned and expressed Y. 
pseudotuberculosis (termed YCNFy) in E.coli (termed ECNFy). Analyzes with both Yersinia and E.coli 
CNFy for multinucleation in NuLi1 cells confirmed that YCNFy was 8 times more active than ECNFy. 
Comparative proteomics unveiled a greater  PTM value of 61 in the Yersinia CNFy compared to that 
expressed in E. coli with a modification of only 6 amino acids. Out of all, only Lysine 1003 is 
“methylation” was found to be common in both YCNFy and ECNFy whereas 17 glutamic acid 
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methylation could only be found in YCNFy suggesting that PTM is required for the activity of CNFy. 
This study thus describes some novel and stirring characteristics of Y. pseudotuberculosis MVs and 
CNFy. Follow-up studies designed to utilize such unique findings should extend the scope of Y. 
pseudotuberculosis research regarding infection prevention and control.  
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Chapter 1 
Introduction 
1.1 Host-microbe interaction and pathogenesis 
Host-microbe interactions are as assorted as the organisms involved. They can be accidental or 
obligatory, temporary or persistent, and they can involve elusive or intense host response. But the 
outcome of the host is simple: health or disease. There are three well-known interactions between the 
host and microbe at the anatomical level. 1) Mutualism: in this, the microorganism and the host are 
equally benefited. For example, cattle and the rumen microflora. 2) Commensalism: in this kind of 
interaction, either the host or the microorganism experiences benefits while the other is not affected. 
Normal flora inhabiting in the eyes can be an example of this type of interaction. 3) Parasitism, also 
known as antagonism: in parasitism, one organism benefits at the expense of the other. For example, 
parasites use the human or animal gastrointestinal tract as an environment to colonize and reproduce. 
Pathogenic microbes come under this category. However, any microorganism considered a pathogen 
should be follows Koch’s postulate1. But pathogenesis doesn’t always end with disease manifestation. 
Pathogens cause diseases in selective hosts, and pathogens are distinguished from one another by their 
expressions of virulence factors. The interaction between pathogen and host is required for the disease 
progression2; however, not all host-pathogen interactions result in disease3. More recent views, 
originating primarily from studies of bacterial virulence, continued to focus on the ability of a pathogen 
to cause disease. The virulence property of a microbe has been used to describe a microbial 
characteristic4. 
Pathogenic bacteria have both virulence and immune evasion strategies, which may involve 
hiding from the immune system, interfering with the function of the immune system, and destroying 
elements of the immune system. Virulence comprises the use of various mechanisms to kill or cause 
the malfunction of host cells5. Various bacterial components interact with the host system (Fig.1.1). 
Namely, capsules, which protect pathogens from phagocytosis, are a natural defense mechanism of the 
host whereby pathogenic microbes might be engulfed and killed by host immune cells6. Additionally, 
lipopolysaccharide (LPS) and outer membrane components may lead to septic shock,7 and toxins can 
serve to damage host cells.8 Most pathogens are intracellular, and some do not necessarily invade the 
host cell but use various secretion processes to deliver toxins and other virulence factors to the host cell 
to help the invasion as well as proteins to facilitate attachment to the host cell9. Once a pathogen is 
attached to a host surface, it invades host tissues9 and may travel further inside them by expressing and 
secreting enzymes to digest host extracellular matrix proteins and polysaccharides.10 
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Fig 1.1 Various bacterial components interact with the host system. 
1.2 The delivery of virulence factors via secretion systems 
Bacteria are equipped with an inclusive variety of highly specialized mechanisms that secrete 
a range of molecules, including proteins and DNA11. Secretion systems are an important aspect of gram-
negative bacteria and offer distinct advantages over the cell-associated material. Use of secretion 
systems to deliver bacterial factors to the host cell is a common strategy whereby pathogens induce 
uptake. Secreted molecules have significant roles in the response of a bacterium to environmental 
factors and several pathogenic events, such as adhesion, adaptation, and growth12. Based on the 
secretion system, the secreted substrates have three possible destinies: they remain allied with the 
bacterial outer membrane, they are injected into a target cell, or they are released into the extracellular 
space. Six secretion systems (Types I to VI) by which bacteria deliver virulence factors to the host 
system have been identified. Secreted material is typically considered to be soluble; however, 
prokaryotes and eukaryotes have specific mechanisms to secrete insoluble molecules. A study has 
revealed that gram-negative bacterial membrane vesicles (MVs), insoluble secretion pathways released 
from the envelopes of growing bacteria, serve as secretory vehicles for various cellular components of 
those bacteria. 
1.3 Membrane vesicles (MVs) 
Gram-negative bacteria have a specialized architecture of cell envelopes which split into two 
membranes known as the inner and outer membranes 13. The peptidoglycan layer and the periplasmic 
space differ in lipid and protein composition. In most gram-negative bacteria, the outer membrane is 
composed mainly of LPS and phospholipids14. Between two membranes there is a viscous periplasmic 
space of approximately 13 nm which comprises approximately 7 to 40 percent of the total cell volume15. 
The cell envelop contains a large number of proteins which assist in several biological processes, such 
as nutrient acquisition, adherence, secretion, signaling, and protection from the environment16. Any 
stress to the envelope is lethal to the bacterium. To overcome environmental stress, gram-negative 
bacteria have evolved multiple mechanisms to monitor and repair damage caused by envelope stressors. 
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Gram-negative bacteria release membrane vesicles and periplasm through the production of MVs, small 
spherical structures 20 to 250 nm in diameter17. The existence of membrane vesicles first came to light 
when a cell-free filtrate of Vibrio cholerae was able to elicit an immune response in rabbits. As the 
outer membrane components of these bacteria are highly immunogenic, it was suspected that the 
components of the outer membrane (OM) were somehow leaching into the medium18. Later, it was 
shown that E. coli cultures grown on a lysine-limiting medium secreted LPS in the form of spherical 
structures which later released spherical membrane-bound vesicles19, which was produced by pinching 
off the OM in V. cholera 20. Similar studies have revealed the chemical composition of MVs present in 
outer membrane components and other cellular compartments. These structures have been variously 
termed ‘membrane vesicles’, ‘extracellular vesicles’, and ‘outer membrane fragments’. The term ‘outer 
membrane vesicles’ is regularly used today21. 
 
MVs are produced when small portions of the OM bulge away from the cell, pinch off, and 
release. Soluble proteins are associated with MVs as entrapped periplasm and as externally adherent 
material. Secreted MVs can disseminate far from the cell and impart 22. All types of gram-negative 
bacteria have been seen to produce MVs in a variety of environments, including in planktonic cultures, 
in fresh and salt water, in biofilms, and inside eukaryotic cells.22 Within mammalian hosts, MVs play a 
crucial role in the interaction of bacteria with their environment and have been found to mediate and 
promote diverse functions, including pathogenesis, quorum signaling, nutrient acquisition, horizontal 
gene transfer, survival during stress, regulation of bacteria–bacteria interaction, and antibiotic 
resistance23. 
 
MV production is a common mechanism, and gram-negative MV formation has presumably 
evolved for a reason. Many studies of MVs have been directed at determining MV composition and 
functions24. Although several mechanisms for vesiculation have been proposed, it is presumed that 
vesiculation occurs by a well-conserved mechanism21; however, different types of MVs may exist and 
originate from different mechanisms. Also, subpopulations of MVs with distinct compositions may 
exist within a bacterial culture although MV population heterogeneity is a facet of the field that has yet 
to be explored in much depth21. Importantly, the field has suffered from scepticism, often as a result of 
initially unreliable terminology, as vesicles resulting from bacterial lysis were not differentiated from 
intact MVs for careful experimentation on MVs production and cargo and the mechanisms regulating 
these processes. 
 
All gram-negative bacteria release MVs in every stage of growth and a range of different 
environmental conditions.21 MVs aid bacteria in the secretion of soluble and insoluble cellular 
materials,21 and although they contain many of the cellular components found within the parent 
bacterium, they are non replicative.25 Previous analyzes of MVs from various pathogenic bacteria have 
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suggested that they contain LPS, peptidoglycan, periplasmic and membrane-bound proteins,26 toxins,27 
DNA,28 and RNA.29 The key event of outer biogenesis includes outward protuberance of areas lacking 
membrane–peptidoglycan bonds. As well, membrane vesicle production is enhanced without a loss of 
outer membrane integrity, inclusion or exclusion of certain proteins and lipids, or membrane pilfering 
without direct investment of energy from ATP/GTP hydrolysis.21 Secreted as insoluble and soluble 
bacterial envelope components, MVs are poised to play innumerable biological roles. An important 
feature of MVs is that the proteins associated with them exhibit biological activities. MVs act as delivery 
vehicles, as nucleates in the formation of bacterial communities (biofilms), and as contributors to 
bacterial survival and virulence. Nonvesiculated mutants have not been identified so far, but many genes 
whose alterations change have been identified. 
1.4 Biogenesis of membrane vesicles (MVs) 
Biogenesis of vesicles is regulated and does not result from or cause fractures in the outer 
membrane. It involves the packaging of proteins and lipids without the use of adenosine triphosphate 
(ATP) or other energy sources directly at the site of budding,31. In sum, vesiculation likely results from 
non exclusive events that depend on physiological circumstances or species. A series of events occurs 
during vesicle biogenesis, the first of which is the un budding of gram-negative envelopes. In this event, 
envelope proteins, including OM–peptidoglycan linking proteins, are distributed. The first step toward 
creating an MV is outward bulging of the outer membrane30. This event implies that buds form in areas 
where proteins linking the OM to the peptidoglycan layer are absent, which could occur if the 
peptidoglycan is disrupted, such as with antibiotics or autolysins. This could result in the release of 
MVs containing peptidoglycan fragments and portions of OM–peptidoglycan bridging proteins. 
Although this model accounts for increased vesiculation during envelope disruption, it is not likely the 
main mode of vesiculation. 
 
Vesiculation can be increased by over a hundredfold without affecting membrane integrity31, a 
feat hard to imagine if the peptidoglycan layer were heavily degraded. Other envelope events could 
trigger MVS budding. For example, OM–peptidoglycan links can be removed via target disruption. 
Evidence exists to support both models. As the linking protein OmpA is depleted but present in MVs 
and is excluded, simply relocating the links would provide the benefit of maintaining membrane 
integrity. Peptidoglycan links are present even if vesiculation is highly upregulated. 
However, simply removing OM–peptidoglycan links does not suffice for the mechanism of MV 
formation because it does not consider that overexpressed and misfolded periplasmic proteins can cause 
budding and that specific proteins are enriched or excluded in MVs30. Some proteins concentrate at the 
inner leaflet of the outer membrane, thereby creating stress on the membrane, but budding occurs only 
after peptidoglycan linkages are removed from the outer membrane. This would increase the odds of a 
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bud forming when the links were removed and would allow vesiculation to be upregulated by the 
accumulation of periplasmic material as well as by the removal of OM–peptidoglycan linking proteins. 
Specific gathering of particular proteins at these sites would enrich these proteins in the MVs21. 
Alternative to or in addition to periplasmic turgor pressure, curvature-inducing molecules could cause 
membrane bulging. Localized concentration of curvature-inducing molecules leads to breakage of the 
underlying OM–peptidoglycan links after those membranes bud off. This event leads to enrichment of 
these molecules in MVs, as observed with molecules of P. aeruginosa32. Additionally, molecules which 
induce curvature will interact with specific periplasmic proteins and cause enrichment of particular MV 
cargo. In each situation, vesicle production is regulated by the accumulation and diffusion of envelope 
proteins. It is often proposed that MVs released from the cell when the bud grows to the point at which 
membrane curvature forces separation33. However, it is not clear that this happens. MVs are found in a 
variety of sizes, indicating that no critical threshold of curvature precipitates their release. 
1.5 Factors influencing vesicle production 
MV production is distinct from systems secreting soluble proteins. In MV secretion, the soluble 
material is released in a complex with or surrounded by insoluble material. Various environmental and 
physiological changes lead to the production of vesicles, for example, temperature, nutrient availability 
(low or high), vesiculation, and growth conditions. Cells growing at an exponential rate produce more 
MVs, and septation during cell division is one of the critical stages of MV production, possibly because 
of increased peptidoglycan turnover during cell division.30 
1.6 Virulence factors associated with membrane vesicles 
Various reports on membrane vesicles suggest that they are associated with virulent proteins.32 
These virulence factors include stress-related proteins, toxin adhesion, and other enzymes as well as 
known protein antigens such as LPS (Table 1). Membrane vesicles can act as a delivery vehicle for 
virulence factors by communicating with both prokaryotic and eukaryotic cells.22 Recently, Maldonado 
et al. have demonstrated the hemolytic and leukotoxic activity of MVs internalized by human 
osteoblasts and synovial cells.34 These cells produce increased levels of human granulocyte-
macrophage colony-stimulating factor (GM-CSF) and interleukin 6 (IL-6).34 A recent report has shown 
an association between MVs and invasion-related proteins in Shigella flexneri.35 Recombinant 
attachment invasion locus proteins forming Yersinia entercolitica expressed in E. coli vesicles show a 
higher degree of invasion compared to non-recombinant ones.36 This suggests that the attachment-
invasion  locus (Ail) protein is associated with membrane vesicles and contributes to the internalization 
of membrane vesicles. MVSs also transport a variety of ions, quorum-sensing signals, and metabolites. 
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Table 1. Toxins associated with membrane vesicles 
 
  
SL no. Bacteria Toxin Reference 
1 A. actinomycetemcomitans Cytolethal distending toxin 37 
2 Escherichia coli O157:H7 Shiga toxin 38 
3 Vibrio cholera Cholera toxin 20 
4 Uropathogenic E.coli Cytotoxic Necrotizing Factor 1 27 
5 Helicobacter pylori Vacuolating toxin (VacA) 39 
6 Escherichia coli ClyA cytotoxin 40 
7 Kingella kingae RTX (repeat-in-toxin) toxin 34 
8 Bordetella pertussis Pertussis toxin 41 
9 Photorhabdus luminescens Toxin AB 42 
10 Actinobacil 
pleuropneumoniae 
Apx toxin 43 
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Table 1.2. Virulence factors associated with native membrane vesicles 
SL no. Species Vesicle-associated virulence factor Reference 
1 Shigella flexneri IpaB, IpaC, IpaD 44 
2 Actinobacillus pleuropneumoniae proteases 43 
3 Bacteroides fragilis Hemagglutinin 45 
4 Bacteroides succinogenes Cellulase, xylanase 46 
5 Photorhabdus luminescens Toxin AB, GroEL  42 
6 Pseudomonas aeruginosa Phospholipase C,  47 
7 Salmonella enterica  Protective antigens  48 
8 Shigella flexneri IpaB, IpaC, IpaD (Invasion) 49 
9 Treponema denticola Dentilysin, adhesins, proteases  50 
10 Vibrio anguillarum Metalloprotease, hemolysin, 
phospholipase  
51 
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1.7 Advantage of membrane vesicles over bacterial secretion systems 
Membrane vesicles offer distinctive advantages over other bacterial secretion systems, as they 
can protect virulence determinants from host proteases and concentrate them for host cell delivery.52 In 
addition, MVs can simultaneously deliver multiple virulence factors, MV-associated adhesions can 
provide tissue-tropic delivery of MV content,53 and MVs can confer antibiotic resistance.23 It should be 
appreciated that other basic physiological functions of MVs (see above) and their association with 
biofilms also contribute to bacterial pathogenesis by increasing bacterial adaptation and survival in the 
hostile host environment.54 Intriguingly, both harmful and beneficial effects have been linked to MV 
production by bacteria present in the host gut microbiota.55 Protein and virulence factors in membrane 
vesicles are inaccessible to proteases or peptidases.56 Membrane vesicles help drug-resistant bacteria 
survive during antibiotic treatment and improve the biofilm formation abilities of pathogens.23 Recent 
reports have revealed that bacteria use vesicles as long-distance delivery vehicles. MVS antigens 
disperse to sites far from initial colonization, such as the urine, blood, and some organs of Borrelia 
burgdorferi–infected mice, dogs, and humans.57 
1.8 The genus Yersinia 
Yersinia sp. is a rod-shaped facultative anaerobic gram-negative bacteria belonging to the 
enterobacteriaceae family. Out of its eleven species, only three, namely Yersinia pestis, Yersinia 
entercolitica, and Yersinia pseudotuberculosis, are considered important human pathogens. Yersinia 
pestis, well known as the causative agent of plague, is found chiefly in rodents and their fleas.58 Other 
animals might carry it as well, but 85 percent of infections are caused by flea bites.59 Yersinia 
entercolitica is the more common Yersinia species associated with foodborne infections. It is also 
reported to cause inflammatory bowel disease. This pathogen is transmitted via the faecal–oral route, 
most often by eating or drinking contaminated food or water.60 It can also spread by coming in contact 
with infected animals or people.61 This organism is most commonly found in raw pork or pork products 
such as pig intestines.62 
1.9 Yersinia pseudotuberculosis and its virulence 
Yersinia pseudotuberculosis is found in various environments like water.63 There are also reports of its 
distribution within wild and domestic animals.64 Yersinia pseudotuberculosis causes acute 
gastroenteritis and mesenteric lymphadenitis.65 Although Y. pseudotuberculosis infections are 
distributed worldwide, Y. pseudotuberculosis is mostly invasive in nature compared to other species of 
Yersinia. During the invasion, Y. pseudotuberculosis expresses invasin (INV), attachment invasion 
locus (AilA) proteins, and adhesion (YadA) proteins, all of which mediate tight adhesion and entry into 
mammalian cells through β-integrins.66 It also harbours a 70 kb virulence plasmid known as pYV. This 
plasmid encodes the Yersinia outer proteins (Yops), which include YopE, YopH, YopJ, YopM, YopT, 
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YpkA, and YopK.67 Upon immediate contact with a target host cell, these Yops are delivered to it via a 
mechanism involving the Type III Secretion System (T3SS).68 Aside from these, the Y. 
pseudotuberculosis cytotoxic necrotizing factor (CNFy) has been identified within host cells during 
infection and even contributes to the activity of the Yops.69 However, the mode of delivery for CNFy 
and several other Y. pseudotuberculosis proteins remains unclear.69-70 To date, membrane vesicle 
production in Yersinia pseudotuberculosis has not been reported. Recently published studies have 
described how bacterial pathogens employ MVs as vehicles to transport virulence factors and deliver 
them to host cells.71 As such, MVs represent a novel and potent bacterial secretion mechanism that 
bypasses the need for direct contact between the bacterium and the host cell,21, 72 does not require typical 
secretion machinery such as the T3SS and is exhibited by diverse pathogens.53, 73 Moreover, one can 
easily envision a scenario in which a pathogen that incorporates invasive factors in its outer membrane, 
such as the AilA protein of Y. pseudotuberculosis, uses its MVs as vehicles to deliver virulence factors 
to host cells. Consequently, the production of MVs by Y. pseudotuberculosis and their potential 
involvement in pathogenesis, particularly in the delivery of virulence factors, has been investigated 
within this study. 
 
Fig.2 Response of host system to bacterial membrane vesicles  
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Chapter 2  
Yersinia Pseudotuberculosis Membrane Vesicles Deliver Virulence Factor 
into Human Airway Epithelial Cell (NuLi-1) 
 
2.1 Abstract 
Membrane vesicles (MVs) are gaining much importance lately because of their bi-directional role in 
bacterial physiology and pathogenesis. Here we reported that Yersinia pseudotuberculosis, an important 
food-borne enteric pathogen produces membrane vesicles (MVs). 24 hour grown Y. pseudotuberculosis 
was associated with the production of MVs as revealed by transmission electron and super resolution 
microscopic analysis. Further characterization of the purified MVs were performed by SDS-PAGE, 
however, revealed significantly different protein profiles compared to proteins from stationary phase 
cells. Further proteomic analysis by LC-MS/MS, we identified 887 vesicular proteins with high 
confidence by three separate runs. Result revels vesicle contains a number of secreted bacterial proteins, 
including 60kDa chaperonin (GroEL), urease and attachment invasion locus proteins (AilA).  Based on 
subcellular localization predictions, MVs composed of an outer membrane, periplasmic and 
cytoplasmic proteins. Further studies with human airways epithelial cells, purified MVs induced 
morphological changes in human airways epithelial cells and MVs were shown to be cytotoxic as they 
internalized by human airways epithelial cell. 
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2.2 Introduction  
Yersinia pseudotuberculosis is a Gram-negative enteric pathogen that is believed to be a direct 
evolutionary ancestor of Yersinia pestis, the causative agent of the bubonic plague74. As a pathogen, Y. 
pseudotuberculosis causes foodborne diseases in humans and zoonotic infections in a variety of wild 
and domestic animal hosts 75. This bacterium is transmitted via the fecal-oral route where, after entry 
into the host, it penetrates the intestinal epithelium by initially infecting Peyer's patches and spreads 
after that to the lymphatic system and the mesenteric lymph nodes76. In humans, Y. pseudotuberculosis 
is associated with several medical conditions, including the gastrointestinal disease yersiniosis 77, 
mesenteric lymphadenitis 78, fatal septicemia 79 and at times they may lead to post-infectious reactive 
arthritis 66a, 79-80. 
Y. pseudotuberculosis has evolved an exquisite method for delivering virulence factors and 
effectors into cells of the host immune system where they inhibit signaling cascades and block the cells 
response to infection81. Moreover, adhesion molecules and a Type III secretion system are critical for 
the establishment and progression of the infection82. This pathogen expresses the invasin (INV), 
attachment invasion locus protein (AilA) and adhesion (YadA) proteins, all of which mediate tight 
adhesion and entry into mammalian cells through β-integrins 66, and also harbors a 70-kb virulence 
plasmid known as pYV. This plasmid encodes the Yersinia outer proteins (Yops), which include YopE, 
YopH, YopJ, YopM, YopT, YpkA and YopK67a, 67b. Upon intimate contact with a target host cell, these 
Yops are delivered into the host cell via a mechanism involving the Type III Secretion System (T3SS)68. 
Asides from these, the Y. pseudotuberculosis cytotoxic necrotizing factor (CNFy) has been identified 
within host cells during infection and even contributes to the activity of the Yop proteins69. However, 
the mode of delivery for CNFy and several other Y. pseudotuberculosis proteins in the milieu of host 
cells remain unclear69-70. 
Many Gram-negative bacteria, both pathogenic and non-pathogenic, have been shown to 
produce membrane vesicles (MVs)71. Although the exact reason for their production is not always clear, 
MVs can contain biologically active proteins and play various roles in diverse biological processes, 
including biofilm formation and the potential to critically impact disease progression71. For instance, 
recently publicized studies describe how bacterial pathogens employ MVs as vehicles to transport 
virulence factors and deliver them into host cells 83 71. As such, vesicles represent both a novel and 
potent bacterial secretion mechanism that by-passes the need for direct contact between the bacterium 
and the host cell 21, 72, does not require typical secretion machinery, including T3SS, and is exhibited by 
diverse pathogens 53, 73. Moreover, one can easily envision a scenario where a pathogen that incorporates 
invasive factors in its outer membrane, such as the AilA protein of Y. pseudotuberculosis, uses its MVs 
as vehicles to deliver virulence factors into the host cells. Consequently, the production of MVs by Y. 
pseudotuberculosis and their potential involvement in pathogenesis, particularly in the delivery of 
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virulence factors, was investigated within this study.  To the best of our knowledge, this is the first ever 
study reporting production and virulence association of MVs from Y. pseudotuberculosis. 
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2.3 Materials and Methods  
2.3.1 Bacterial strain and growth condition   
Yersinia pseudotuberculosis ATCC29833 obtained from KACC South Korea and Y. 
pseudotuberculosis YPIII with virulence plasmid (+) NR4380 obtained from Biodefense and emerging 
infections research resources repository (BEI Resources, USA) and E. coli NlpI obtained from Keio 
collections(Keio group, Japan). Strains were maintained as frozen 20% glycerol stocks at -80°C. Upon 
need, this strain was grown on Luria-Bertani agar plates (BD; Difco, USA) at 30°C overnight. From 
this plate, a single colony was inoculated into 5 ml of LB broth and grown overnight at 30°C with 
agitation (250 rpm) florescent Yersinia strains were developed by transferring pAmCyan  plasmid 
(Promega, USA) 
2.3.2 Culture of human airway epithelial cell line (NuLi-1 Cells) 
Bronchial epithelial cell (NuLi-1) (ATCC CLR 40110) obtained from ATCC were cultured in T75 
flasks in bronchial epithelial cell growth medium (BEGM; Lonza, USA) substituted with antibiotic 
Normocin, 100 µg/ml (Invivogen, USA), until they were confluent. Cells were then washed with sterile 
DPBS and trypsinized for 5 min to detach from the flask. Cells were then washed with complete 
medium, counted using hemocytometer and diluted appropriately to seed in an appropriate culture dish 
for the experiments. 
2.3.3 Culture of human breast epithelial cell line (MCF-10A Cells)  
Mammary gland/breast epithelial cells (MCF-10A) were cultured in T75 flasks in Dulbacco’s Modified 
Eagle’s Medium (DMEM-F12 1:1 with 15 mM HEPES; Gibco, USA). The media is substituted with 
5% heat-inactivated fetal bovine serum (ATCC, USA), 20ng/ml of EGF, 10 µg/ml of insulin (Sigma-
Aldrich, USA), and 100 µg/ml of Normocin until they were confluent. Then cells were washed with 
sterile DPBS and trypsinized 5 min detached from the flask. Cells were then washed with complete 
medium, counted and diluted appropriately to seed on the plate required for the experiment. 
2.3.4 Cloning of 60kDa chaperonin and CNFy  
60 kDa chaperonin from both Y. pseudotuberculosis ATCC 29833 and YPIII (+) and  CNFy 
from Y. pseudotuberculosis YPIII(+)  were amplified by PCR from genomic DNA using gene specific 
primers (Table 2.6) , thereby introducing restriction sites for restriction enzymes Xba1 and Xho1. The 
resulting PCR product was ligated into the expression vector pET31b+ and transformed into E. coli 
Dh5α. After confirmation of insert, the plasmid harboring CNFy or 60kDa chaperonin were transformed 
into Y. pseudotuberculosis and E. coli NlpI. 
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2.3.5 Purification of CNFy and 60kDa chaperonin 
Y. pseudotuberculosis YPIII(+)  harboring  pET31B+ CNFy,  Y. pseudotuberculosis  ATCC 
29833 Harboring 60kDa chaperonin both strains were grown in LB medium with antibiotic 
ampicillin 100μg/ml.  Then incubated at 30°C until the bacteria reaches optical density of  OD 
1.0. Then cells were collected by centrifugation the resulted pellet were suspended in lysis 
buffer(50 mM Tris-HCl pH 7.5; 200 mM NaCl) then supplemented with lysozyme (1mg/ml). 
Suspension kept in ice for 30 minutes before sonication. After 30 min cells had been sonicated 
lysate were centrifuged to remove the cell debris. Further lysate were purified by affinity 
chromatography on Ni-NTA agarose (Qiagen; USA). loaded beads were washed with lysis 
buffer (with 20mM imidazole) at 4 °C. The CNFy  and chaperonin  were eluted from the beads 
(500mM imidazole with lysis buffer ) twice for 10 min at room temperature 
2.3.6 Determination of plasmid pET31b+ copy number in Y. Pseudotuberculosis by Real-time 
qPCR  
To determine the copy number of plasmid we followed previously reported protocol with slight 
modifications84.  Yersinia pseudotuberculosis ATCC 29833 and Yersinia pseudotuberculosis YPIII (+) 
harboring pET31b (+) plasmid were cultured in 15 ml of LB media 50 ml conical tube at 30°C and 
37 °C. Total DNA was extracted from each of the cultures during the exponential growth phase 0.8 OD 
by periodic measurement of optical density (OD) at 600 nm. The extraction was performed using the 
DNA purification Kit (Cosmo, South Korea), the template DNA extracted from Y. pseudotuberculosis 
was normalized to 1ng/μl. The concentration of extracted DNA was measured using Nano drop 
(thermos scientific, USA). The prepared template DNA was analyzed to quantify bla and CNFy 
triplicate in real-time qPCR assay. Real-time qPCR amplification and analysis were performed using a 
Light cycler instrument with software version 3.5 (Roche Diagnostics). The threshold cycle (Cp) was 
determined with standard Cp value for the CNFy Which cloned in pET31b (+). The vector the copy 
number theoretically calculated. CNFy in both Yersinia was used as internal control in Yersinia has a 
single copy of CNFy.  
 
2.3.7 Membrane vesicle isolation 
Purification of the membrane vesicle is based on the previous protocol with slight modifications. 
Cultures of Y. pseudotuberculosis ATCC 29833 or YPIII (+) were grown in 500ml LB broth for 24 
hours as described above. The cells were removed by pelleting (4000xg, 20 min) and then filtering the 
supernatants twice with 0.22-micron filtration units (Stericup; Millipore, USA). The MVs present in the 
supernatant were then concentrated using a 100-kDa tangential filtration concentration unit (Amicon 
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Ultra-15; Millipore USA) to approximately 5 ml. Subsequently, they were pelleted (40,000×g, 2 hours) 
and suspended in 1 ml of 25 mM phosphate buffered saline (PBS, pH 7.2). The concentration of MVs 
was quantified based on the protein content using the Bradford colorimetric assay method (Life 
Technologies, USA). 
2.3.8 Quantification of MVs by FACS  
Yersinia pseudotuberculosis ATCC 29833 and E.coli NlpI were used to determine the 
production of MVs by FACS.  E.coli NlpI secretes a high number of MVs so initial FACS gate setting 
was done using purified E.coli NlpI MVs. To determine MVs production by Y. pseudotuberculosis 
ATCC 29833 bacteria were grown in LB media at 30°C in shaking incubator. The optical density was 
measured at different time points, the cell-free supernatant at each time point were collected by pelleting 
the bacteria by centrifuging at 5000 RPM 20 min followed by filtration through 0.22-micron filter. 
Collected cell free media were analysis by FACS, FSC gated population were recorded for 30 seconds 
for each sample MVs number calculated based on the flow rate of the FACS system. 
2.3.9 Determination of toxicity of Y. pseudotuberculosis ATCC 29833 cell free media   
It was reported that Y. pseudotuberculosis spent media was toxic to the mammalian cell.  
To confirm Yersinia pseudotuberculosis, ATCC29833 were grown in LB media at the aerobic 
and semi-aerobic condition for 24 hours. Spent media were collected, by removing bacteria by 
centrifugation at 5000 RPM for 20 min followed by 0.22 micron filtration. Toxicity of the cell 
free media on NuLi-1 cell were determined by MTT assay.    
2.3.10 Observation of MVs using TEM and super-resolution microscopy (SR-SIM) 
For electron microscopy, MVs were purified as mentioned above. 2µl of MVs/bacteria culture 
were placed on carbon-coated Formvar grids (Polysciences, Inc., USA). The samples were treated with 
2.5% glutaraldehyde for 1 hour. Excess fixing agents were eliminated during the dehydration of samples 
as they were washed sequentially in a series of an aqueous solution containing increasing amounts of 
ethanol and finally in absolute acetone. The samples were then negatively stained with 0.1% uranyl 
acetate and examined under a transmission electron microscope (JEOL 1200 EX, USA) present in the 
UNIST central research facility (UCRF). To obtain the super-resolution microscopy image, 
concentrated MVs were labeled with rhodamine B-18 (Life Technologies, USA) for 20 min. After 
staining, unbound dye was removed by ultracentrifugation at 40000 rpm for 2 hours. Concentrated MVs 
were diluted in PBS. Approximately 5 μl (100 μg/ml) of MVs were visualized under a super-resolution 
microscope (ELYRA S.1 super-resolution structured illumination [SR-SIM]; Carl Zeiss, Germany) 
operated by Zen 2012 software. 
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2.3.11 Visualization of internalized MVs by confocal microscopy  
 
For microscopy, a monolayer of human cells was prepared on 8 well-chambered cover glass 
(Nunc® Lab-Tek® II Thermo Scientific) by seeding 1X104 human airway epithelial cells/well and 
incubated in a CO2 incubator at 37ºC for 24 hours. Before MVs treatment, human airway epithelial cells 
were stained with CFSE by replacing media with 0.5ml of CFSE/CMTPX (Molecular probe: Invitrogen, 
USA ) in PBS final concentration of 5µg/ml and incubated at 37ºC in a CO2 incubator for 10 min. After 
incubation, cells were washed twice with PBS and added to 0.5 ml of BGEM media. Stained cells were 
incubated for 1 hour at 37ºC in a CO2 incubator with 5% CO2. For invasion assay, purified MVs stained 
with rhodamine BR-18/ as mentioned above stained MVs or MVs from CFP expressing Yersinia diluted 
to 10ug/ml in BGEM media. Initially, well was replaced with 0.5 ml of BGEM with MVs and without 
MVs as a control was incubated for 2 hours at 37ºC. After incubation, unbound MVs were removed and 
replaced with 0.5 ml of BGEM media. For time-lapse imaging, cultured cells were treated with purified 
vesicle from CFP expressing Yersinia pseudotuberculosis YPIII (+) strain and 20 μg/ml of vesicle were 
treated to each well. Cells were incubated for 2 hours. An unbound vesicle was removed after 2 hours 
and washed with DPBS 3 times; then cells were replenished with fresh complete media and imaged at 
different interval of using LSM 700 laser scanning confocal microscope (Carl Zeiss, Germany) operated 
by ZEN 2009. 
2.3.12 Proteomic Analysis of Y. pseudotuberculosis Vesicles  
 
To identify proteins associated with the outer membrane vesicle, purified vesicle preparations (12 μg) 
were applied to 12% Tris-glycine SDS-PAGE gel (Bio-Rad, USA). After staining with Coomassie blue, 
the each band separated into 6 were subjected to in-gel tryptic digestion, as described by Shevchenko 
and co-workers 85. The resulting tryptic peptides were analyzed by LC-MS/MS. All mass analysis were 
performed on an LTQ-Orbitrap (Thermo, Bremen, Germany) equipped with a nanoelectrospray ion 
source. To separate the peptide mixture, we used a C18 reverse phase HPLC column (150mm x 75um 
i.d.) using an acetonitrile/0.1% formic acid gradient from 10 to 24% for 90min at a flow rate of 300 
nl/min.  
For MS/MS analysis the precursor ion scan MS spectra (m/z 400–2000) were acquired in the 
Orbitrap at a resolution of 60,000 at m/z 400 with an internal lock mass. The 20 most intensive ions 
were isolated and fragmented in the linear ion trap by collisionally induced dissociation (CID).All 
MS/MS samples were analyzed using Sequest (Thermo Fisher Scientific, San Jose, CA, USA; version 
1.4.1.14) and X! Tandem (The GPM, thegpm.org; version CYCLONE (2010.12.01.1)). Sequest and X! 
Tandem were set up to search the Y. pseudotuberculosis protein sequence database (9823 entries, 
UniProt (http://www.uniprot.org/)) assuming the digestion enzyme trypsin.Sequest and X! Tandem 
were searched with a fragment ion mass tolerance of 0.60 Da and a parent ion tolerance of 10.0 PPM. 
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Carbamidomethyl of cysteine was specified in Sequest and X! Tandem as a fixed modification. 
Deamidated of asparagine and glutamine, methyl of glutamic acid, lysine, glutamine and arginine, 
oxidation of methionine, acetyl of lysine, serine, threonine and the n-terminus and phospho of serine, 
threoneine and tyrosine were specified in Sequest and X! Tandem as variable modifications. Glu->pyro-
Glu of the n-terminus, ammonia-loss of the n-terminus, gln->pyro-Glu of the n-terminus were specified 
in X! Tandem as variable modifications. 
2.3.13 Criteria for protein identification 
Scaffold (version Scaffold_4.4.3, Proteome Software Inc., Portland, OR) was used to validate MS/MS-
based peptide and protein identifications. Peptide identifications were accepted if they could be 
established at greater than 95.0% probability to achieve an FDR less than 1.0% by the Scaffold Local 
FDR algorithm. Protein identifications were accepted if they could be established at greater than 99.0% 
probability to achieve an FDR less than 1.0% and contained at least 2 identified peptides. Protein 
probabilities were assigned by the Protein Prophet algorithm 86. Proteins that contained similar peptides 
and could not be differentiated based on MS/MS analysis alone were grouped to satisfy the principles 
of parsimony. Proteins are annotated with GO terms from NCBI (downloaded Aug 1, 2014). 87 
2.3.14 Cell viability and cytotoxicity assays  
The toxic effects of purified MVs in-vitro were analyzed by quantitatively determining cell 
viability of human airway epithelial (HAE) cell line, NuLi-1 (ATCC CLR 40110). In 96 well plate 50% 
confluent airway epithelial (HAE) was prepared and treated with 100ul of 10ug/ml of MVs in BGEM 
media added into each well and incubated 72 hours at CO2 incubator. Briefly, MTT solution (5 mg/ml) 
was added to each well in an amount equal to 10% of the culture medium volume. Cells are incubated 
for two h at 37°C; absorbance was measured at a wavelength of 540 nm, and the percentage of viable 
cells were calculated as the ratio of absorbance of stained cells. 
 
2.3.15 Immunostaining of F-actin 
To study the influence of the MVs on actin cytoskeleton rearrangements, a monolayer of NuLi-1 was 
incubated with purified MVs or PBS for 3 hours. Subsequently, cells were fixed with 4% 
paraformaldehyde (in PBS) overnight at 4ºC temperature after fixation cells were washed with PBS and 
permeabilized with 0.1% Triton X-100 (Sigma-Aldrich, USA) in PBS for 5 min. The actin cytoskeleton 
stained with phalloidin rhodamine (0.5 µg/ml PBS; Invitrogen, USA) for 1 hour at room temperature. 
Cells were washed with PBS and the nuclei stained with DAPI (1 µg/ml in PBS) for 5 min at room 
temperature. Cells were visualized using a laser confocal microscope (LSM 700 and the Zen program 
(Zeiss, Germany). 
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2.3.16 Western blotting  
The samples of cellular protein from treated and untreated cell extracts separated by sodium dodecyl 
sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and then electro blotted onto a 
polyvinylidene difluoride (PVDF) membrane. The immunoblot was incubated for 2 hours with blocking 
solution (5% (wet/vol) skim milk Difco), followed by incubation for 2 hours with Anti His-tag antibody 
conjugated to HRP. Blots washed with Tween 20/Tris-buffered saline (TBST, 20 mM Tris-HCl buffer, 
pH 7.6), containing 137 mM NaCl and 0.05% (vol/vol) and images using LAS 200 System (GE 
Healthcare, USA).  
2.3.17 Semi-quantitative analysis of the chaperonin in MVs 
MVs were purified from both Y.pseudotuberculosis ATCC29833-Chap and Y. 
pseudotuberculosis YPIII(+)-Chep. Chaperonin were purified from Yersinia 
pseudotuberculosis ATCC 29833-Chap by affinity chromatography Using Ni-NTA agarose as 
mentioned previously, the purified chaperonin were quantified using Broadford assay. A 
known concentration of the chaperonin and MVs loaded to SDS page followed western blotting 
using anti-his tag HRP conjugate(Abcam, USA). 
2.3.18 Quantification of CNFy by ELISA  
For quantification 10 µg of MVs prepared by treating with or without 0.1% TritonX. A know the 
concentration of purified recombinant CNFy expressed in YPIII (+) used as a standard. Both standard 
and purified MVs were coated on costar 96 well plate using a coating buffer (0.1M sodium bicarbonate 
buffer; pH 9.6) incubated for 2 hours at room temperature then blocked by adding 200μL of blocking 
buffer (1% BSA in washing buffer to each well). Incubate for 30 minutes at 37°C. Wash plate 3 times 
with 200 μL of wash buffer. Add of HisProbe-HRP1:5000 dilutions. Put working solution to each well 
and incubate for 15 minutes at room temperature. Wash plate 4 times with 200μL of wash buffer. Add 
50µl Color reagent A and B (R and D systems, USA) incubated for 30 min at room temperature, then 
reaction were stopped by adding solution (R and D Systems, USA) was added and allowed to develop 
color then measured absorbance at 450 nm. 
2.19 Quantification of multinucleation 
To determine the multinucleation, NuLi-1 cells (2000 cells/well) were seeded on grown 96 well-plate 
or 24 hours with 5% CO2 then incubated with the different concentration of MVs for 48 hours. in a CO2 
incubator with 5% CO2 were stained with CMTPX red then incubated with the. After incubation cells 
were washed with DPBS ( Sigma-Aldrich, USA ) and fixed with 4.0 % of paraformaldehyde for 10 min 
at room temperature. Fixative were removed by washing three times with DPBS and by washing, and 
fixed cells were counterstained with DAPI( 5µg/ml(Invitrogen, USA) . Then cells were visualized under 
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the confocal microscope (LSM 700: Carl Zeiss, Germany) at the magnification 20X and images 
captured using Zen 2009 software.Multinucleated cells were visually counted and calculated percentage 
of multinucleated cells. 
2.3.20 Confirmation of packaging of the 60 kDa Chaperonin  
To determine the packaging of chaperonin the MVs form Y. pseudotuberculosis ATCC 29833 was 
purified at different time point MVs concentration was determined by Bradford assay from 
each time point 15ug of MVs were analyzed by SDS-PAGE.Further confirmation to 
demonstrate chaperonin only abundant in the MVs it is not abundant in the whole cells MVs 
and whole cell from wild-type Y. pseudotuberculosis ATCC29833 and YPIII(+) and 
recombinant with Y.pseudotuberculosis ATCC 29833-Chap YPIII-Chap was  prepared.  Both 
whole cell and  MVs samples were boiled with SDS-PAGE loading buffer then concentration of protein  
was determined by Broadford assay. 15ug of protein from each sample were loaded to SDS-PAGE for 
silver staining and by western blotting.        
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2.4 Result and discussion   
2.4.1 Yersinia pseudotuberculosis Secretes membrane vesicles (MVs) 
Filtered (0.22µm), cell-free spent media from cultures of Yersinia pseudotuberculosis ATCC 29833 
grown overnight under several different conditions (Fig 2.1) was found to be harmful to NuLi-1 airway 
epithelial cells, reducing their viability (Fig 2.2). Although the degree of impact varied somewhat based 
on the growth conditions used for the pathogen, the dose-dependent nature of all the samples suggested 
that some effector(s) was present in the cell-free supernatants.  
Recently, several groups demonstrated that various pathogenic bacteria produce and secrete membrane 
Membrane vesicles (MVs), but this was not verified for Y. pseudotuberculosis. Consequently, we 
imaged Y. pseudotuberculosis ATCC 29833 using transmission electron microscopy (TEM). As shown 
in Fig 2.3), we found MVs clearly associated with and budding off of the bacterial cells. Subsequently, 
as cultures of Y. pseudotuberculosis ATCC  grew, 0.22µm-filtered supernatant samples taken and the 
number of MVs within each was determined via FACS counting (Fig 2.4) after first labeling the MVs 
with Rhodamine B-R18, a membrane binding dye that generates a strong red fluorescent signal as 
shown in (Fig 2.5) The number of MVs within the cultures continually increased as Y. 
pseudotuberculosis ATCC grew but was more pronounced once the cultures entered the stationary 
phase. Although the sizes of the MVs in (Fig 2.3) and other TEM images varied greatly between 
approximately 20 nm to 400 nm in diameter, the sizes were more clearly visible after purification 
(Fig2.6).  
2.4.2 Y. pseudotuberculosis MVs are Double MVs 
In addition to FACS enumeration, labeling of the purified MVs with rhodamine B-R18 allowed us to 
visualize them using super-resolution confocal microscopy (Fig 2.5). Unexpectedly, when MVs were 
purified from cyan fluorescent protein (CFP) expressing Y. pseudotuberculosis ATCC 29833 cultures, 
they fluoresced green (Fig 2.5). The clear and widespread presence of CFP, a cytoplasmic protein, 
within the secreted MVs strongly implied that many of the Y. pseudotuberculosis ATCC29833   MVs 
that were purified are double-membrane. Another related and important idea that stemmed from this 
observation was that the MVs also harbored other cytoplasmic proteins and possibly known virulence 
factors. A comparative analysis of the proteins present within the whole cells and those in the purified 
MVs using SDS-PAGE gel showed they were quite distinct from one another (Fig 2.7). One clear 
example of this was the presence of a dominant 60 kDa band in the MVs preparation. Using mass 
spectrometry, a total of 879 proteins that spanned the entire stratum of the bacterium, from the 
cytoplasm to the outer membrane (Tables 2.2 to 2.5), were identified within the Y. pseudotuberculosis 
ATCC29833 MVs. The cytoplasmic fraction comprised the largest grouping, with 484 proteins (55%) 
(Fig 2.8). Table 2.1 lists the top thirty proteins identified according to the number of hits, with 
cytoplasmic proteins occupying the top four spots. The large presence of cytoplasmic proteins within 
the Y. pseudotuberculosis MVs further affirms that they are a double membrane. Moreover, the two 
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most abundant proteins identified were virulence factors - the 60 kDa chaperonin and the alpha-subunit 
of urease, which has a size of 61 kDa. Combined, these two proteins constituted more than 83% of all 
hits seen in the LC-MS-MS analysis for the purified MVs, a finding that strongly supports the SDS-
PAGE results presented in Fig 2.5. 
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Fig 2.1 Growth of Y. pseudotuberculosis ATCC 29833 at different conditions. OD at 600nm was 
measured after 24 hours.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2.2 Viability of NuLi-1 cells after treatment of Y. pseudotuberculosis ATCC 29833 spent media. 
Cell-free supernatant from 24 hours grown Y. pseudotuberculosis at different growth condition was 
collected. Cell-free supernatant were treated on a monolayer of NuLi-1 cells then the viability of cells 
were determined by MTT assay after 48 hours of treatment. 
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Fig 2.3 Transmission electron microscopy (TEM) image of Y. pseudotuberculosis ATCC29833 
producing MVs. 24 hour grew Y. pseudotuberculosis ATCC29833 culture were subjected to TEM 
imaging. MVs are clearly associated with and budding off of the bacterial cells (Scale bar 500 nm)  
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Fig 2.4 FACS analysis to quantify the MVs production within each time point/ growth stages.  
a) OD of Y. pseudotuberculosis ATCC 29833 at different time points represented. b) Vesicle 
production by Y. pseudotuberculosis ATCC 29833 quantified by FACS analysis.   
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Fig 2.5 Super resolution microscopy (SR-SIM) Image of purified MVs. 2 µg of MVs were stained 
with rhodamine BR-18 or 2µg purified MVs from CFP expressing Y. pseudotuberculosis ATCC29833 
were imaged under super resolution microscope  (Scale Bar 500nm) 
 
 
Fig 2.6 TEM images of purified MVs from Y. pseudotuberculosis ATCC29833. It clearly shows 
heterogeneous population of MVs the size is varied greatly between approximately 20 nm to 400 nm in 
diameter (scale bar 200nm) 
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2.4.3 Packaging of Chaperonin into the MVs 
Table 1 lists the most common protein as the 60-kDa chaperonin. The strikingly high-level presence of 
this protein within the MVs suggested that it was being packaged. To study this further, a recombinant 
His-tagged chaperonin in the pET31b vector was expressed within Y. pseudotuberculosis ATCC29833. 
Using antibodies specific for this epitope, the presence of the chaperonin within both the whole cell and 
the MV fractions was assayed (Fig 2.5). No cross reactivity was seen when the control samples, i.e., 
wild-type whole cells or MVs, were probed using this antibody. However, immunoblots of the 
recombinant samples show that the quantity of chaperonin within the MVs was much greater than that 
of the corresponding whole cells. Semi-quantification of the chaperonin present in the MVs was 
performed using purified recombinant protein as a standard (Fig 2.6) and suggests that the MVs may 
contain as much as ten-times more chaperonin per microgram of protein than the whole cells. It should 
be considered that the complementation of chaperonin with plasmid will lead to increase in the gene 
copy number. So we determined the copy number of the pET31b(+) plasmid in Y. pseudotuberculosis 
ATCC 29833 and YPIII (+) strain by qPCR method using CNFy as an internal control( single copy in 
chromosome).  Result confirms the strains grown at 30°C copy number was found to be 60 and 35  of 
peT31B+ plasmid ATCC29833 and YPIII(+)  at 37°C  copy number was 35 and 41  in ATCC29833 
and YPIII (+) respectively  (Fig 2. 20  and Table 2.6 ) 
 The high level presence of the chaperonin protein within the vesicles was also seen in other 
bacterial pathogens, including Franscella 88, giving credence to our findings but also implying 
that this chaperonin may be being packaged into MVs. When the proteins within MVs from E. 
coli were identified, we once more found the chaperonin from this bacterium to be one of the 
most concentrated proteins. Although not definitive, the continued high-level presence of the 
chaperonin within MVs of different bacterial species suggests that MVs may be a common 
means employed by virulent bacteria to disseminate this virulence factor to the host cells. As 
such, the mechanism used by bacteria to package the chaperonin into MVs is clearly an area 
that needs to be studied further. This apparent packaging of the chaperonin into the MVs was not 
growth stage dependent as MVs purified from cultures grown for 4, 8, 12 hours contained. 
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Fig 2.7 Comparative analysis of the proteins present within the whole cells and those in the 
purified MVs.  Std is the protein marker, wild type bacteria (WC) membrane vesicle from wild-type 
bacteria (MV) recombinant bacteria expressing Chaperonin (rWC) MVs from recombinant 
bacteria( rMV). For SDS-PAGE gel analysis sample were treated with SDS- Sample buffer then 
quantified by Bradford assay 15ug of protein from each sample loaded. Subsequently performed Silver 
staining and  western blotting Using anti-His HRP conjugate. 
 
 
 
Fig 2.8 Pie chart showing subcellular localization of protein associated with Y. pseudotuberculosis 
ATCC 29833 MVs. Subcellular localization was determined by using PSORTb database.  
 
28 
 
 
2.4.4 Y. pseudotuberculosis MVs Invade Human Cells and Cause Multinucleation 
As a human pathogen, Y. pseudotuberculosis is probably best known for its ability to invade 
into human cells via a β-actin mediated endocytotic mechanism involving the bacterial INV or AilA 
proteins (The ability of this strain to invade NuLi-1 airway epithelial cells illustrated in Fig2.10, where 
CFP-expressing whole bacterial cells are evident within the epithelial cells shortly after their addition. 
Tests with the MVs purified from Y. pseudotuberculosis ATCC  cultures also retain the ability to invade 
as shown by the CFP-fluorescent MVs visibly present within the human epithelial cells (Fig 
2.10).Further confirmation MVs were stained with Rhodamine BR-18, stained MVs were allowed to 
Invade NuLi-1 (Fig 2.9) cell and MCF 10a Cells( Fig 2.10) result confirmed the MVs were internalized 
in NuLi-1 and MCF-10a Cells Time lapse Image of YPIII+ vesicle treated cells shows the vesicle can 
be retained inside the cells up to 24 hours (Fig 2.17)  
One may easily surmise from the data in Table 2.1 and Figs 2.8 that the MVs are being used to introduce 
the associated virulence factors into the human cells when they invade. This was confirmed in Fig 2B 
as the recombinant chaperonin could be detected within the infected human cells via western blotting 
(Fig 2.13). For each sample, 20 µg of total protein was separated by SDS-PAGE.  
Not only are virulence factors being transported by MVs but they also appear to be active as 
clear dose-dependent phenotypic responses were elicited from the exposed NuLi-1 epithelial cells (Fig 
2.14 and 2.15).  Fig 2.15 shows epithelial cells exposed for 3 hours to 10 µg/ml of purified Y. 
pseudotuberculosis ATCC MVs displaying extensive β-actin rearrangement. Similar results were also 
obtained when MVs from Y. pseudotuberculosis YPIII (+) were tested. Likewise, in both tests, an 
exposure to the MVs also led to the formation of giant cells, a phenotype associated multinucleated 
cells  
Moreover, the viabilities of the epithelial cells at 48 hours decreased in a dose-dependent 
manner as greater quantities of purified MVs were added, with a 5 and 10 µg/ml addition of Y. 
pseudotuberculosis ATCC  MVs leading to a 50% and 70% loss in viability, respectively (Fig2.14). 
Parallel tests performed using MVs purified from Y. pseudotuberculosis YPIII (+) found slightly weaker 
but similar dose-dependent losses (Fig 2.14). To further assert that the toxicity resulted from the MVs 
and not some other soluble protein present within the preparation, the purified MVs were removed by 
100kD filtration. When the filtrates from both Y. pseudotuberculosis strains were tested, no adverse 
effect on the viability was observed (Fig 2.16). Moreover, pre-treatment of the purified MVs with either 
heat or proteinase K before their addition significantly or completely alleviated their toxicity, 
respectively (Fig 2.14).  
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2.4.5 Y. pseudotuberculosis MVs Transport CNFy into Human Cells 
Although the MVs from both Y. pseudotuberculosis strains led to similar losses in viability and 
widespread β-actin rearrangement and fiber formation within the epithelial cells, one clear difference 
between the MVs from these two related strains was seen in their ability to cause multinucleation (Fig 
2.18).  Whereas the degree of multinucleation was dose-dependent for both preparations, these Figs 
show that the Y. pseudotuberculosis YPIII (+) MVs are far more potent and lead to a significantly 
greater degree of multinucleation than those from Y. pseudotuberculosis ATCC 29833.  
 
Multinucleation of the human cells strongly hinted at the presence of the cytotoxic necrotizing 
factor (CNFy), a known virulence factor leading to this phenotype It is also known that the gene 
encoding for CNFy is full-length in Y. pseudotuberculosis YPIII (+) (3.1 kb) but is truncated in Y. 
pseudotuberculosis ATCC  (1.8 kb), which helps to explain the different phenotypes seen with the 
exposed epithelial cells70 To determine if CNFy is being transported with the MVs, and that the full-
length protein can account for the differences seen for these two pathogens, the full-length CNFy gene 
(3.1 kb) was cloned and expressed within Y. pseudotuberculosis ATCC 29833. As shown in (Fig 2.18), 
expression of the full-length CNFy gene within this host led to significantly more multinucleation and 
at a level that is analogous to that seen with Y. pseudotuberculosis YPIII (+) MVs.  That was, confirming 
that the CNFy protein is responsible for this phenotype and that it is very likely associated with MVs. 
To confirmed the presence of CNFy in the MVs initially western blot analysis was not succeeded due 
to CNFy further the MVs sample were subjected to ELISA (Fig 2.15) and confirmed CNFy present in 
the MVs  
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Fig 2.9 Semi-quantitative analysis of the chaperonin present in the MVs. Semi-quantification of the 
chaperonin present in the MVs was performed using purified recombinant protein as a standard.  
 
 
 
 
 
 
 
Fig 2.10 Packaging of chaperonin in MVs at the different time point of Y. pseudotuberculosis 
ATCC29833 growth. MVs purified at different time points 4, 8, 12 and 15µg of MVs subjected to 
SDS-PAGE page followed coomassie blue staining.  
 
 
 
 
  M             4h           8h           12h 
31 
 
 
 
 
 
Fig 2.11 Invasion of Yersinia pseudotuberculosis ATCC 29833 MVs into NuLi-1 cells Image shows 
localization of Y. pseudotuberculosis live bacteria, and MVs invaded into airways epithelial cell, 85% 
confluent epithelial cell were stained with cell tracker CMTPX- Red stain then co-cultured with CFP 
expressing Y. pseudotuberculosis approximately 200 bacteria/cell (bacteria). 10ug purified MVs from 
CFP expressing bacteria were treated to the cells (MVs). After 2 hours non invaded bacteria and MVs 
were remove by washing with DPBS and media were replaced with media supplemented with 
antibiotics time and imaged using laser conafocal microscope white arrow indicate location of 
MVs.( Scale bar 10 µm) 
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Fig 2.12 Rhodamine BR-18 labeled MVs invaded into with NuLi-1 cells. Image shows localization 
of Y. pseudotuberculosis ATCC 29833 invaded MVs inside the airways epithelial cell, 85% confluent 
epithelial cell were stained with cell CFSE cell proliferation stain then treated with 10µg of purified 
MVs for 2 hours. After incubation, non-invaded MVs were removed by washing with PBS 3 times and 
imaged using laser confocal microscope yellow arrow, indicate location of MVs (Scale bar 10 µm) 
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Fig 2.13 Rhodamine BR-18 labeled MVs invaded into with MCF-10a cells. Image shows 
localization of Y. pseudotuberculosis ATCC29833 invaded MVs inside the airways epithelial cell, 85% 
confluent epithelial cell were stained with cell CFSE cell proliferation stain then treated with 10µg of 
purified MVs for 2 hours. After incubation non invaded MVs were removed by washing with PBS 3 
times and imaged using laser confocal microscope yellow arrow, indicate the location of MVs (Scale 
bar 10 µm) 
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Fig 2.14 Recombinant 60kDa chaperonin detected within the mammalian cells.  NuLi-1 cells were 
treated with 20 ug of Purified MVs which from Y. pseudotuberculosis ATCC29833-Chap and YPIII(+)- 
Chap. MVs were allowed to invade for 2 hours then treated cells were washed with DPBS to remove 
unbound MVs   then  cells were trpsinzed  the trypsinzed cells were boiled with SDS-PAGE sample 
buffer then 20 µg of total protein was separated by SDS-PAGE subsequently analysed by western 
blotting using Anti -His HRP conjugate. mC is the media control, rMV- MVs with recombinant His-
tagged 60kDa Chaperonin control (20 ug of MVs) invaded MVs into  NuLi-1 cells. 
 
 
Fig 2.15 Viabilities of the NuLi-1 after 48 hours of MVs treatment. The viability of NuLi1 cell 
decreased in a dose-dependent manner as greater quantities of purified MVs were added, with a 5 and 
10 µg/ml addition of Y. pseudotuberculosis ATCC  MVs leading to a 50% and 70% loss of viability.  
 
 
 mC             rMV       mMV     MC          rMV        mMV  
ATCC 29833 YPIII (+) 
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Fig 2.16 Purified Y. pseudotuberculosis ATCC29833  and YPIII (+) MVs displaying extensive β-
actin rearrangement after 3hour of treatment with 10 µg/ml MVs. 10 µg/ml Purified MVs from the 
both strain to the NuLi-1 cells for 3 hours. After treatment cells were washed and fixed with 3.7 % of 
paraformaldehyde and washed with DPBS then stained Rhodamine-phalloidin, counterstained with 
DAPI then image were taken by confocal microscopy at 100X magnification (scale bar 20µm) 
 
 
 
 
 
 
36 
 
 
 
 
 
Fig 2.17 Cytotoxic effect of Different fraction of Y. pseudotuberculosis MVs on NuLi-1 cells. 
Toxicity of MVs on NuLi-1 cell. To confirm the toxicity resulted from the MVs and not some other 
soluble protein purified MVs Subjected to Different treatments.  Media No MVs (Control) Vesicle 
(10µg/ml) 100kDa filtration flow thought (Filtered), heat treated MVs (Heat) Vesicle treated with 
Proteinase K (Pro K). 
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2.18. Time lapse image shows localization of Y. pseudotuberculosis YPIII(+) MVs invaded into 
Nuli-1. 85% confluent epithelial cell were stained with cell tracker CMTPX- Red  20 µg purified MVs 
from CFP expressing Y. pseudotuberculosis YPIII (+) were treated with the cells. After 2 hours unbound 
MVs were removed by washing with DPBS then cells are replenished with fresh media supplemented 
with antibiotics.  Time lapse image were taken at different time intervals (Scale bar 10µm) 
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Fig 2.19 Determination of multinucleated cells after treatment of MVs a) Percentage of 
multinucleated cells were determined by imaging followed by counting. The used various concentration 
of MVs 1.5ug to 10 µg. Vesicle from ATCC29833 YPIII+ and ATCC29833 with recombinant CNFy. 
b) Representative image of cells treated with 10µg of MVs. 
 
 
b) 
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Fig 2.20 Quantification of CNFy associated with MVs by ELISA using His-Probe HRP conjugate 
a) SDS –PAGE gel and western blot analysis of purified CNFy purified CNFy were loaded at different 
concentration.  b) 10µg of purified membrane vehicle were treated with 0.1% of triton X and non-
treated were coted on 96 well plate. Know concentration of purified CNFy-His expressed in YPIII (+) 
was used to plot the stranded curve.  
 
 
b) 
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Table 2.1 Pathogenesis-related protein associated with Y. pseudotuberculosis ATCC29833 MVs  
 
 
 
 
 Protein Uniprot ID MW  Peptides Localization 
1 60 kDa chaperonin CH60_YERP3 57 kDa 4941.167 Cytoplasmic  
2 Urease subunit alpha  URE1_YERP3 61 kDa 757.2433 Cytoplasmic 
3 Urease subunit beta  B1JR70_YERPY 17 kDa 166.7433 Cytoplasmic 
4 Peptidase B  PEPB_YERPB 47 kDa 224.19 Cytoplasmic 
5 Attachment invasion locus protein  AIL_YERPS  20 kDa 67.337 Outermembrane  
6 Peptidase M16  B2JZ59_YERPB 108 kDa 39.81133 Cytoplasmic 
7 Outer membrane protein,  A7FI37_YERP3 23 kDa 34.664 Outermembrane 
8 Protease Do  B1JK15_YERPY  50 kDa 33.20533 Unknown 
9 Protein tyrosine/serine phosphatase B1JP79_YERPY  31 kDa 30.96733 Cytoplasmic/membrane 
10 Outer membrane protein A A7FJS9_YERP3  39 kDa 30.604 Outermembrane 
11 Porin Gram-negative type  B1JS88_YERPY 41 kDa 24.68667 Outermembrane 
12 Lipoprotein A7FFJ7_YERP3  29 kDa 21.01333 Outermembrane 
13 Lipoprotein B2K715_YERPB 23 kDa 20.41167 Outermembrane 
14 Peptidase M48  B2K0S3_YERPB 27 kDa 20.07467 Cyto/ membrane  
15 Peptidase M24  B2K0Q9_YERPB 49 kDa 18.62567 Cytoplasmic/membrane 
16 Major outer membrane lipoprotein  LPP_YERPS 8 kDa 15.04 Outermembrane 
17 Phospholipase  B1JIM9_YERPY 52 kDa 12.0846 Outermembrane 
18 General Bacterial Porin  Q66CG8_YERPS 40 kDa 11.74393 Outermembrane 
19 Peptidase M22 B1JLJ4_YERPY  25 kDa 11.02333 Cytoplasmic 
20 Peptidase U32  B1JLW5_YERPY 37 kDa 10.7027 Cytoplasmic 
21 Oligopeptidase A  A7FP13_YERP3  77 kDa 9.608067 periplasmic 
22 17 kDa surface antigen  B1JJ74_YERPY 15 kDa 9.589833 Unknown  
23 Aminopeptidase N  B2JYR6_YERPB  98 kDa 9.507533 Cytoplasmic 
24 Putative lipoprotein  Q66AB7_YERPS 29 kDa 5.871033 Outermembrane 
25 Oligopeptidase B  B1JP33_YERPY  79 kDa 6.0087 Cytoplasmic 
26 Peptidase M24  B1JME6_YERPY 45 kDa 4.9846 Cytoplasmic 
27 Putative chaperone protein  B1JSE3_YERPY 49 kDa 4.4743 periplasmic 
28 Putative lipoprotein  B1JPB8_YERPY 19 kDa 5.118867 Outermembrane 
29 Phospholipase A  Q7B171_YERPU 34 kDa 3.941933 Outermembrane 
30 Hemolysin YERP3-DECOY - 1.297867 Outermembrane 
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Table 2.2 Outer membrane protein associated with Y. pseudotuberculosis ATCC29833 MVs  
 
 
 
 
 
 
 
 
 
S.No  Protein  Uniprot ID MW/Kda Peptide No 
1 Attachment invasion locus protein  AIL_YERPS 20 kDa 67.337 
2 Outer membrane protein, OmpW  A7FI37_YERP3 23 kDa 34.664 
3 Outer membrane protein A  A7FJS9_YERP3  39 kDa 30.604 
4 Nitrilase/cyanide hydratase and apolipoprotein  B1JKG9_YERPY  32 kDa 30.40133 
5 Porin Gram-negative type  B1JS88_YERPY 41 kDa 24.68667 
6 Lipoprotein  A7FFJ7_YERP3  29 kDa 21.01333 
7 Lipoprotein  B2K715_YERPB 23 kDa 20.41167 
8 Outer membrane protein assembly factor  B1JS08_YERPY 42 kDa 16.71167 
9 Major outer membrane lipoprotein  LPP_YERPS 8 kDa 15.04 
10 Phospholipase D/Transphosphatidylase  B1JIM9_YERPY 52 kDa 12.0846 
11 General Bacterial Porin (GBP) family protein  Q66CG8_YERPS 40 kDa 11.74393 
12 VacJ family lipoprotein B1JGF8_YERPY 28 kDa 8.775433 
13 Type III effector Hrp-dependent outers B1JS75_YERPY  46 kDa 8.449733 
14 Outer membrane protein assembly factor BamA BAMA_YERP3 88 kDa 6.949067 
15 Membrane protein   B1JGF9_YERPY  45 kDa 6.6753 
16 Outer membrane protein assembly factor BamC  B2K994_YERPB 38 kDa 5.8878 
17 Putative lipoprotein Q66AB7_YERPS 29 kDa 5.871033 
18 Maltoporin 1  LAMB1_YERP3 47 kDa 5.306767 
19 Phospholipase A  Q7B171_YERPU 34 kDa 3.941933 
20 Hemolysin YERP3-DECOY   --- 1.297867 
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Table 2.3: Top 20 cytoplasmic proteins associated with Y.pseudotuberculosis ATCC 29833 MVs 
 
 
 
 
 
 
 
S. No Protein  Uniprot ID MW/kDa Peptide No 
1 60 kDa chaperonin CH60_YERP3 57 kDa 4941.167 
2 DNA-directed RNA polymerase subunit beta rpoC  RPOC_YERP3 155 kDa 1516.633 
3 DNA-directed RNA polymerase subunit beta rpoB  RPOB_YERP3 150 kDa 1225.427 
4 Pyruvate dehydrogenase E1 component A7FM42_YERP3 100 kDa 930.2833 
5 Urease subunit alpha ureC  URE1_YERP3 61 kDa 757.2433 
6 Pyruvate dehydrogenase,  Q66EH9_YERPS 55 kDa 682.23 
7 Iron-containing alcohol dehydrogenase  B1JKU8_YERPY 97 kDa 645.0133 
8 DNA-directed RNA polymerase subunit alpha rpoA  RPOA_YERP3 37 kDa 498.52 
9 Glutamine synthetase  B1JR07_YERPY 52 kDa 437.7567 
10 Malate dehydrogenase  B1JSJ4_YERPY 82 kDa 425.0067 
11 Aspartate ammonia-lyase  B1JMR4_YERPY 53 kDa 354.41 
12 Ribose-phosphate pyrophosphokinase B1JM90_YERPY 34 kDa 348.0467 
13 FAD dependent oxidoreductase  B1JHY2_YERPY 57 kDa 246.3333 
14 Peptidase B PEPB_YERPB 47 kDa 224.19 
15 Glyceraldehyde-3-phosphate dehydrogenase, type I  B1JLG3_YERPY 36 kDa 213.9867 
16 Phenylalanine-tRNA ligase beta subunit SYFB_YERPS 87 kDa 205.2767 
17 Ribonuclease R  B1JMN1_YERPY 95 kDa 200.96 
18 Citrate synthase OS=Yersinia pseudotuberculosis  B1JG64_YERPY 48 kDa 191.2867 
19 Formate acetyltransferase  B1JRE6_YERPY 85 kDa 181.3467 
20 Urease subunit beta ureB  B1JR70_YERPY 17 kDa 166.7433 
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Table 2.4: Periplasmic proteins associated with Y. pseudotuberculosis outer MVs 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
S.No  Protein  Uniprot ID MW/kDa Peptide No 
1 Protein TolB  TOLB_YERP3 46 kDa 15.706 
2 L-asparaginase, type II  B1JRE3_YERPY 36 kDa 14.22033 
3 Aldose 1-epimerase  B1JLG4_YERPY 32 kDa 10.03797 
4 Glycerophosphodiester phosphodiesterase B1JP88_YERPY 27 kDa 7.509633 
5 Oligopeptidase B  B1JP33_YERPY  79 kDa 6.0087 
6 Thiol:disulfide interchange protein  B1JR14_YERPY 23 kDa 5.442867 
7 Murein tripeptide ABC transporter  A7FHP5_YERP3 60 kDa 5.256533 
8 Ecotin  ECOT_YERP3 19 kDa 4.522933 
9 Putative chaperone protein  B1JSE3_YERPY 49 kDa 4.4743 
10 Oligopeptide/dipeptide ABC transporter, ATPase subunit  B1JJR9_YERPY 38 kDa 4.232433 
11 Oligopeptide/dipeptide ABC transporter, ATPase subunit  B1JKU2_YERPY 37 kDa 3.293933 
12 Formate dehydrogenase-O, major subunit  Q663U7_YERPS 113 kDa 3.260433 
13 Putative periplasmic beta-glucosidase A7FE47_YERP3  80 kDa 1.945867 
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Table 2.5 Bacterial plasmid and primers used in this study 
 
 
Strain or plasmid  Description/genotype Reference  
Y. pseudotuberculosis ATCC 29833 Wild type strain - 
Y. pseudotuberculosis YPIII + Wild type strain - 
Y. pseudotuberculosis ATCC 29833 
CFP 
Y. pseudotuberculosis ATCC 29833 with 
pAmcyan 
This study 
Y. pseudotuberculosis YPIII CFP Y. pseudotuberculosis YPIII(+) with 
pAmcyan 
This study 
Y. pseudotuberculosis ATCC 29833-  
Chap  
Y. pseudotuberculosis ATCC 29833 With 
pET31b-Chap-His 
This study 
Y. pseudotuberculosis YPIII(+)- Chap Y. pseudotuberculosis YPIII (+) Chap-His This study 
Y. pseudotuberculosis29833 CNF Y. pseudotuberculosis ATCC 29833 With 
pET31b-CNFy-His 
This study 
Y. pseudotuberculosis YPIII(+) CNFy Y. pseudotuberculosis YPIII (+) CNFy-His This study 
E .coli DH5-Alpha   
 E .coli BW NlpI chap E coli BW NLpI pET31b-Chap-His This study 
E.coli BW NlpI CNF E coli BW NlpI pET31b-CNFy-His This study 
Plasmids   
pAmCyan  Plasmid expressing pAmCyan  
Pet 31b + Expression Vector  
Pet 31 B+ Chap Plasmid expressing  Chaperonin  This study 
Pet 31 b+ CNFy Plasmid expressing CNFy This study  
Primers     
Chap F            5’ AATCTAGATGTGAAAGTCGGCGACGTCG  3’                          This study 
Chap R             5’ATTCTCGAGCATCATGCCGCCCATGC  3’                                 This study 
CNF F              5’TATTCTAGATTTTACATGTAATAATAAATAGCAG3’              This study 
CNF R             5’ATACTCGAGAAAGTCTTTTTGTAAAACATTAAAC3’              This study 
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Fig 2.21 based on Cp value obtained from qRT PCR. Standard curve drawn for cytotoxic 
necrotizing factor CNFy and beta-lactamase gene  
 
 
Table 2.6 The copy number of the pET31b+ plasmid in both Y. pseudotuberculosis strain at different 
growth condition 
 
 
 
 
 
 
 
 
 
 
 
 
 
Strains 
Condition 
Gene copy/ µl 
Plasmid copy 
30°C CNFy gene       bla gene 
YPIII(+) 2950447 102176230 35.003661(+4.2) 
ATCC29833 2857973 171628443 60.279306(15.37) 
37°C 
YPIII(+) 2821241 106736726 37.846198 (1.55) 
ATCC29833 3085280 129846008   41.640521 (11.16) 
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2.5 Conclusion  
Yersinia pseudotuberculosis produces MVs. Transmission electron microscope and super resolution 
microscopy analysis revealed 24 hours grown Y. pseudotuberculosis was associated with MVs. Further 
proteomic analysis by LC-MS/MS confirmed the 887 vesicular proteins with high confidence by three 
separate runs. The result revealed that MVs contains various virulence factors. Based on subcellular 
localization predictions, MVs are composed of an outer membrane, periplasmic and cytoplasmic 
proteins. Further studies with human airway epithelial cells, purified MVs induced morphological 
changes in human airway epithelial cells, and MVs were shown to be cytotoxic as they are internalized 
by the human airway epithelial cell. Further confirmation, Y. pseudotuberculosis MVs deliver cytotoxic 
necrotizing factor (CNFy) into the host (Fig 2.17). In this study we demonstrated novel secretion system 
which Yersinia utilizes to deliver CNFy and other virulence factors into the host system.   
 
 
 
 
Fig 2.22 Possible mechanism which Y. pseudotuberculosis membrane vesicle deliver virulence factors 
of CNFy and 60kDa Chaperonin into Human cells    
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Chapter 3 
Yersinia pseudotuberculosis Membrane Vesicles Are Cytotoxic and Induce 
TNF-Alfa in Mouse Leukemic Monocyte/Macrophage Raw 264.7 
3.1 Summary  
Yersinia pseudotuberculosis membrane vesicles (MVs) adverse effect on human airway epithelial cells 
(NuLi-1) was confirmed in the previous study. The present study focused on the response of immune 
cells murine macrophage RAW264.7 to MVs. Experimental infection of Y. pseudotuberculosis ATCC 
29833 and YPIII(+) revealed both associated with macrophages after 2 hours of coinfection with MOI 
of 300. Furthermore, murine macrophages were treated with purified MVs from CFP expressing Y. 
pseudotuberculosis ATCC 29833 and Y. pseudotuberculosis YPIII (+) strains. The result suggested that 
MVs are also associated with murine macrophages after 2 hours of treatment. Furthermore, the 
treatment with MVs leads to actin rearrangement after 3 hours of incubation, and there was a significant 
loss in viability after 48 hours of exposure to the MVs. Toxicity was in a dose-dependent manner. 12 
µg/ml of the MVs showed a significant loss in viability, and it was about 53.4 % and 42.1%. 200 µg/ml 
showed 93.84% and 84.6% loss in viability from ATCC29833 and YPIII(+), respectively. The result 
revealed giant cell multinucleated phenotype observed after 48 hours of exposure to MVs. Further study 
showed that macrophages have induced a high level of TNFα response to purified vesicles 5209 pg/ml, 
and 5214 pg/ml TNFα were detected in both ATCC and YPIII(+) vesicle-treated cells, and non-treated 
was 190.6 pg/ml after 24 hours of exposure. Apoptosis assay confirmed ATCC 29833 and Y. 
pseudotuberculosis YPIII(+) MVs treated macrophages that underwent 1.38% and 2.5% apoptosis. 8.3% 
and 9.1% of cells died after 24 hours from cells treated with ATCC29833 and YPIII MVs. The result 
suggests that the apoptosis is not a significant event in cytotoxicity. Further time-lapse image treatment 
with Y. pseudotuberculosis YPIII(+) MVs showed the vesicles are associated with the macrophages 24 
hours of post infection of membrane vesicles.  
3.2 Introduction 
Macrophages, together with other professional phagocytic cells including neutrophils and monocytes, 
play a crucial role in the host-defense system through recognition and elimination of invading 
pathogenic bacteria89. In the initial stage of bacterial infection, immune cells will come in contact with 
the pathogen90. The phagocytosis of the bacteria, the survival or death of macrophages, is crucial for 
the host’s frontline immune defense91. Macrophages either promote their instantaneous survival or 
derail the system-level immune response.92 Gram-negative bacteria secrete virulence factors, and the 
secreted virulence factors are essential for the survival of the bacteria, or they damage the host system9. 
The section of virulence factor is a complicated process because of the complex structure of bacterial 
48 
 
envelope93. Pathogens have various strategies to secrete virulence factors. Virulence factors enable to 
gain access to the extracellular environment, typically the tissues or bloodstream of the host organisms. 
There are various secretion systems: Type I to Type VI. These secretion systems are known to deliver 
virulence factors that are soluble in nature, but the membrane vesicles deliver MVs that are very diverse 
complexes of pathogen-associated molecular patterns (PAMPs),71 such as lipopolysaccharides, 
membrane protein, virulence factors, and cell envelope lipids.94 The composition of MVs is different 
from that of other species, but the lipopolysaccharide structure remains relatively constant within a 
bacterial species.95 The presence of PAMPs, virulence factors, and other outer membrane components 
associated with MVs helps to be recognized by the immune system.96 
 
The host is immune to MVs mainly by the generation of antibodies to the MVs and their components. 
Some studies reported antibody production and protection in response to outer membrane vesicles from 
Neisseria meningitidis97 and Vibrio cholerae98. In contrast, there are relatively few studies 
characterizing how vesicles trigger the innate inflammatory response99. There are a few studies that 
reported inflammatory response from epithelial cells,100, but the macrophage is limited. In the present 
study, we focused on characterizing macrophage responses to the outer membrane vesicles. In some 
reports was shown MVs play an important role in activating innate immune responses101. Given their 
small size and a high proportion of PAMPs, it is reasonable to expect that vesicles could easily infiltrate 
into infected tissues and stimulate widespread inflammation95. In addition to TLR ligands, vesicles also 
contain a variety of protein virulence factors that may specialize vesicles for specific functions or types 
of host cell damage. 
  
Yersinia pseudotuberculosis is a food borne pathogen, and it is transmitted via the fecal-oral route. It 
infects the gut-associated lymphoid tissue.102 It is well known that Yersinia pseudotuberculosis delivers 
YOPs protein via Type III section system to modulate the host’s immune system.69 Cytotoxic 
necrotizing factor enhances the delivery of Yops into murine macrophages that are responsible for 
initiating inflammatory defenses against colonizing bacteria.95 The previous study demonstrated 
Yersinia pseudotuberculosis membrane vesicle is known to contain various virulence proteins and 
purified MVs showed a dose-dependent cytotoxicity and led to actin rearrangement and multinucleation 
in human airway epithelial (HAE) cell line, NuLi-1. In this study, we focused on characterizing the 
response of macrophage to MVs.Yersinia pseudotuberculosis MVs significantly influenced both the 
macrophage morphology and the TNF-alfa responses. Based on this study, we concluded macrophages 
showed a very distinct response to the membrane vesicles. The study suggested that the response is due 
to the effect of heterogeneous factors associated with vesicle protein by macrophages.   
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3.3 Materials and Methods  
3.3.1 Bacteria growth and culture condition  
Y. pseudotuberculosis ATCC 29833 from obtained from KACC and Y. pseudotuberculosis YPIII (+) 
NR-4380 with virulence plasmid(+) was obtained from BEI Resource and was kept in frozen glycerol 
stocks at -80°C. Upon need, bacteria were streaked on a nutrient LB (Difco, USA) agar plate and 
incubated at 30°C overnight. From this plate, a single colony was inoculated into 5 ml of LB broth and 
incubated overnight at 30°C with agitation (200 rpm). The fluorescent bacteria were developed by 
transferring both stains with a pAmCyan plasmid (Promega, USA) and selected in ampicillin 100µg/ml 
plate. The recombinant fluorescent bacteria were grown on Luria-Bertani (LB) plate supplemented with 
ampicillin. 
3.3.2 Mouse leukemic monocyte/macrophage RAW 264.7 cell culture  
The mouse macrophage cell line RAW 264.7 ATCC TIB-71 was obtained from Professor Sang Sun 
Yoon of Yonsei University, Korea. The cells were cultured in DMEM F12 medium (Gibco; Life 
Technologies, NY, USA), supplemented with 10% fetal bovine serum (FBS; ATCC, USA) and with 
hormone 100 mg/ml (InvivoGen, USA) at 37°C with 5% CO2 incubator. 
3.3.3 MVs isolation and purification 
To purify MVs, Y. pseudotuberculosis ATCC 29833-CFP and Y- pseudotuberculosis YPIII (+)-CFP 
followed previously reported method with slight modification. Single colonies were inoculated into 5 
ml of LB broth for 24 hours. Then the overnight grown culture was diluted 1:100 in 500 ml of LB 
ampicillin media in a 2-liter conical flask and incubated at 30°C for 24 hours. After incubation, the cells 
were removed by pelleting (4000 RPM, 20 min) in 500 ml of centrifuge bottle, and then supernatants 
were collected and filtered twice with a 0.22-micron filtration unit (startup and strip; Millipore, USA). 
After filtration, the MVs were concentrated using a 100-kDa tangential filtration concentration unit 
(Amicon Ultra-15; Millipore, USA) to approximately 5 ml. Concentrated MVs pelleted by centrifuging 
at 40,000 RPM for 2 hours were suspended in phosphate-buffered saline (PBS). The concentration of 
MVs was quantified based on the protein content using the Bradford colorimetric assay method. 
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3.3.4 Invasion of Yersinia pseudotuberculosis and purified MVs 
For visualization of invasion, a monolayer of macrophage was prepared on 8 well-chambered cover 
glass (Nunc® Lab-Tek® II; Thermo Scientific, USA) by seeding 2.5X104 macrophage cells/well and 
incubated in a CO2 incubator at 37ºC for 24 hours with 5% CO2. Before MVs treatment, RAW cells 
were stained with cell tracker CMTPX Red (Life Technologies, USA) by replacing media with 0.5 PBS 
containing stain of a final concentration of 5µg/ml and incubated at 37 ºC in a CO2 incubator for 10 
min. After incubation, cells were washed twice with PBS and were added to 0.5 ml of DMEM F12 
media. Stained cells were incubated for 1 hour at 37ºC in a CO2 incubator with 5% CO2. For invasion 
assay, overnight-grown bacteria were diluted in DMEMF12 media up to the final MOI of 300 and 
purified MVs from CFP expressing Yersinia were diluted to 10µg/ml in DMEM F12 media. Initially, 
well was replaced with 0.5 ml of DMEMF12 with MVs incubated for 2 hours at 37 ºC in a CO2 incubator 
with 5% CO2. After incubation had unbound, MVs were replaced with 0.5 ml DMEM F12 media. Then 
cells were imaged at 100x magnification using LSM 700 laser scanning confocal microscope (Carl 
Zeiss, Germany) operated by ZEN 2009 software.  
 
3.3.5 Cytotoxicity assay  
For determining the viability of the cultured host cells, a monolayer of macrophage cells was prepared 
on a 96 well plate by seeding 1X104 RAW cells/well and incubated in a CO2 incubator at 37ºC for 24 
hours. Then it was replaced with 100 µl media. With different MVs, the cells were kept until 48. With 
MVs treatment and the MTT assay done, approximately 40 µl of the MTT reagent were added to each 
well with control and treatment wells and incubated at 37oC for 2 hours in the dark. After incubation, 
the whole liquid was decanted and soaked to remove any remaining liquid in any well by tapping on 
paper towel thoroughly. About 400 µl DMSO were added to each well and incubated with shaking at 
room temperature for 15 minutes. Development of visualized color and OD was measured at 550 nm. 
The viability of cultured RAW cells was proportional to the OD value. 
3.3.6 Apoptosis assay 
For determining the viability of the cultured host cells, a monolayer of RAW was prepared in a 35 mm 
culture dish by seeding 1X105 RAW 264.7 cells /well and incubated in a CO2 incubator at 37ºC with 
5% CO2 for 24 hours. After incubation, the cells were washed twice with DPBS then infected with 1 ml 
purified MVs in DMEM F12 in 10 µg/ml media without MVs as a control. Initially, well was replaced 
with 0.5 ml of DMEMF12 with MVs and without MVs as control and incubated for 24 hours at 37ºC. 
After 24 hours, the cells were trypsinized and washed twice with Dulbecco’s phosphate-buffered saline 
(DPBS). 1X105 suspension cells in 100 μl Annexing V binding buffer were added to 5 μl of Annexing 
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V and PI according to the manufacturer’s recommendations. Incubate the tubes in the dark for 15 
minutes at the room. The stained cells were analyzed by FACS (BD FACS Calibur, USA), and the data 
were analyzed using FlowJo Software.  
3.3.7. Immunostaining of F-actin 
For F-actin staining, a monolayer of RAW cells were prepared on 8 well-chambered cover glass by 
seeding 2.5X104 /well and incubated in a CO2 incubator at 37ºC for 24 hours. To study the influence of 
the MVs on actin cytoskeleton rearrangements, the 24-hour culture was serum starved for 20 hours, and 
then cells were washed with DPBS and incubated with purified MVs 500 µl (5µg) or control media for 
3 hours. Subsequently, cells were fixed with 3.7 % paraformaldehyde (in DPBS) for 20 min at room 
temperature. After fixation, the cells were washed with DPBS and permeabilized with 0.2% Triton-X 
(Sigma-Aldrich, USA) in PBS for 5 min. The actin cytoskeleton was stained with 0.5 µg/ml of 
rhodamine phalloidin (Invitrogen, USA) for 1 hour at room temperature. The cells were washed with 
DPBS, and the nuclei were stained with DAPI 1µg/ml (Life Technologies, USA) in DPBS for 5 min at 
room temperature. The cells were visualized using a laser confocal microscope LSM 700 operated by 
Zeiss, Germany. 
3.3.8 Observation of multinucleation  
To determine the multinucleation, RAW cells (25000 cells /well) were seeded or grown on 96 well plate 
for 24 hours with 5% C02, then incubated with different concentration of MVs for 48 hours. After 
incubation, the cells were fixed with 3.7 % paraformaldehyde for 10 min at room temperature. Fixed 
cells were washed with DPBS and  stained with CMTPX red and DAPI. Then the cells were visualized 
under a microscope at 10X magnification, and taken image. 
3.3.9 Quantification of TNF-alfa 
RAW cells  were grown on a 12 well plate ( SPL, Korea) 5X104 cells/well for 24 hours, and then 
replaced media with vesicle with 10 µg/ml of MVs (5 µg/well) media without vesicle used  as a control  
Treated cells were incubated in a CO2 incubator at 37ºC for 24 hours. After 24 hours, cell culture media 
were collected for ELISA. TNF-α concentration was quantified using ELISA kits from R&D Systems, 
USA, and was performed according to the manufacturer’s instruction. 
 
 
 
 
52 
 
Result and Discussion  
3.4.1 Y. pseudotuberculosis MVs associated with macrophages  
Most of the Y. pseudotuberculosis strains will replicate in the macrophages, except the Y. 
pseudotuberculosis YPIII (+) strain, which is defective in nature and unable to replicate in murine 
macrophages. Replication is independent of type III secretion systems.103 We began our study by 
confirming that Y. pseudotuberculosis invades murine macrophages. Initially, macrophages were 
infected with CFP expressing both ATCC29833 and YPIII (+) (MOI of 300) and 5 µg (10 µg/ml). After 
2 hours of infection, unattached bacteria and MVs were removed by washing with DPBS consequently 
treated with 50µg/ml gentamycin then fixed with 3.7% paraformaldehyde and visualized under a 
confocal microscope. The microscopic image clearly indicates that the Y. pseudotuberculosis live 
bacteria and MVs are associated with macrophages after 2 hours of infection, which stained red 
macrophages associated with CFP expressing live bacteria were invaded and some of the bacteria found 
to be associated with the surface of the RAW cells  (Fig 3.1). The MVs associated with the RAW cells  
were clearly visible (Fig 3.2). The localization of CFP packaged MVs demonstrated that the MVs carry 
cytoplasmic contents. Future treated with only 20 µg/ml YPIII vesicle. The vesicles are associated with 
the macrophage, and initially, after 2 hours, the vesicles were observed in endocytic vesicles, and 
images were taken after 12 hours. When the endocytic vesicles become brighter, it suggests that the 
vesicles are ruptured, or the pH of the endocytosis vesicle was increased. After 24 hours, the vesicles 
seem to be dispersed and the florescence (Fig 3.3). Unfortunately, CFP is very sensitive to acidic pH, 
losing ∼50% of its fluorescence at pH 6.5. The initial stage of coinfection with the vesicle appears to 
be very less florescent. It is believed that the endocytic vesicle will change during endocytosis to reduce 
the lapse image of murine macrophage. It will become one of the brightest and most widely utilized of 
the FPs.  
3.4.2 Y. pseudotuberculosis MVs is cytotoxic to murine macrophage 
In the previous study on airway epithelial NuLi-1 cells, the MVs showed significant cytotoxicity. To 
determine the possible effect of MVs on macrophage, we tested the toxicity of MVs using MTT assay. 
The cytotoxicity of MVs at a different concentration determined by treating RAW cells with 200 µg/ml 
to 3 µg/ml. The viability of cells was after 48 hours of MVs treatment. The result suggested that purified 
MVs are cytotoxic to murine macrophage (Fig 3.3). The viability was decreased in a dose-dependent 
manner. 25 µg/ml of the MVs showed 50% loss of viability. The highest concentration of MVs 200 µg 
was up to 90% loss in viability compared with the 84% to 95% survival of 3 µg/ml MVs treatment (Fig 
3.3). Treatment with ATCC 29833 MVs was significantly more toxic than with YP III (+) vesicles. The 
result was similar to NuLi-1 cell, which suggests that both MVs packaging will be different. The LPS 
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of the bacteria induces cytotoxicity, and MVs also contain LPS. The previous report suggests that 
macrophages were more sensitive to MVs compared with LPS. 104  
3.4.3 Apoptosis is not major event in cytotoxicity  
Membrane vesicle from the pathogenic bacteria showed to induce apoptosis. LPS also one of the 
inducers of apoptosis. In our study, we try to understand the mechanism behind the cytotoxicity so we 
analyzed MVs treated macrophage for apoptosis and necrosis. MVs treated RAW cells were analyzing 
cells by FACS using apoptosis marker Annexin V, the cells were grown on 6-well plate seeded 5X105 
cells/well and incubated for 24 hours in a CO2 incubator with or without membrane vesicle. Then cells 
were trypsinized and stained with Annexin V and propidium iodide, a dead stain. The result suggests 
that around 1.4% and 2.5% ATCC29833 and YPIII(+) MVs treated cells are showing apoptosis 
signature  (Fig 3.4) subsequently stained with propidium iodide around  8.1% and 9.3% ATCC29833 
and YPIII(+) treated cells represented as dead. It suggests that cytotoxicity is not allied with the 
apoptosis. Suggests that there may be other factors responsible for the cell death. Based on the previous 
report on in-vivo studies, the Y. pseudotuberculosis infection leads to inflammation and necrosis, but to 
YopJ, intracellular expression is needed for the survival of bacteria that induce apoptosis.105 
3.4.4 Y. pseudotuberculosis MVs treatment leads to morphological changes in murine 
macrophages RAW 264.7 
Further tests macrophage cells were incubated with purified MVs from ATCC29833,YPIII(+) and, 
respectively. After 4 hours, treated cells were fixed and stained with rhodamine-phalloidin and analyzed 
by fluorescence microscopy. As expected, YPIII (+) MVs induced the actin rearrangement and led to, 
filopodia observed on the cell surface (Fig 3.4). The morphology of cells and MVs-induced actin 
rearrangements observed with YPIII(+) MVs and ATCC 29833, respectively (Fig 3.5), were different. 
As shown in, incubation of RAW cells with 29833 for 4 hours had no effect on the morphology of RAW 
cells and morphology resembled the control cell. Further evaluation, treated cells were incubated for 48 
hours and stained with CMTPX red, and DAPI showed the giant cells phenotype observed, and all cells 
are searched (Fig 3.6) the result suggested that the Y. pseudotuberculosis MVs deliver CNFy, which 
leads to actin rearrangement and filopodia. Further observation revealed that raw cells were treated with 
purified MVs from both YPIII(+) and ATCC 29833 after 48 hours of MVs showed multinucleation (Fig 
3.6). This effect is mainly due to cytotoxic necrotizing factors. 
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3.4.5 Y.  pseudotuberculosis MVs induces secretion of tumor necrosis factor-alpha (TNF-α) 
in murine macrophage 
Murine macrophages were treated with Y. pseudotuberculosis MVs 10 µg/ml from both ATCC29833 
and YPIII (+), media without MVs as a control. After 24 hours, culture media were collected and 
quantified the production of TNF-alfa. The result confirms MVs from both induce a high level of 
proinflammatory cytokine TNF-alfa 5209 pg/ml, and 5214 pg/ml from ATCC29833 and YPIII (+) 
respectively. The tumor necrosis factor alpha cytokine is mainly associated with type I cellular 
immunity. TNF-alfa requires the protection of the host cell from Yersinia infection.106 TNF-α 
counteracts the apoptotic pathway. The activation of MAP kinases and NF-κB, two key components of 
the pro-inflammatory pathway, leads to the secretion of TNF-α.105  
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Fig 3.1 Laser confocal microscope image of Y. pseudotuberculosis ATCC 29833 and YPIII (+) 
associated with murine macrophage RAW 264.7 cells. Overnight-grown Yersinia strain infected to 
RAW cells at the MOI of 300. After two hours of infection, un-infected bacteria were removed by 
washing with DPBS and subsequently treated with 50µg/ml of gentamycin for 15 min and fixed with 
3.7% paraformaldehyde. For visualization, macrophages were stained with CellTracker CMTPX red 
(scale bar 2 µm). 
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Fig 3.2 Confocal image of Y. pseudotuberculosis MVs associated with murine macrophage. 80% 
confluent macrophages were prepared on 8 chambered cover glass. Before infection macrophage was 
stained with CMPTX red.  For visualization of  MVs 5µg (10 µg/ml) purified MVs from CFP expressing 
ATCC 29833 and YPIII (+) were treated with macrophage cells for 2 hours. After two hours, unattached 
MVs were removed by washing with PBS and subsequently treated with 50µg/ml of Gentamycin for 
15 min and fixed with 3.7% paraformaldehyde then visualized under a microscope  (scale bar 2µm). 
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Fig 3.3 Time lapse confocal image of Y .pseudotuberculosis MVs associated with murine 
macrophages. 80% confluent macrophages were prepared on 8 chambered cover glass. Before 
infection macrophage was stained with CMPTX red.  For visualization of  MVs 20µg (40 µg/ml) 
purified MVs from CFP expressing YPIII (+) were treated with macrophage cells for 2 hours. After two 
hours, unattached MVs were removed by washing with BPBS then subsequently added fresh media 
visualized under a microscope at different time points  Arrow indicates the Localization of vesicles 
(scale bar 5µm). 
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Fig 3.4 FACS analysis of macrophages treated with Y. pseudotuberculosis MVs to confirm 
apoptosis. For apoptosis assay macrophages were treated with 1 ml purified MVs in DMEM F12 in 10 
µg/ml media For 24 hours at 37ºC media without MVs used as a control. After 24 hours, of treatment 
cells were trypsinized and washed twice with Dulbecco’s phosphate-buffered saline (DPBS). 1X105 
suspension cells in 100 μl Annexing V binding buffer were added to 5 μl of Annexing V and PI were 
added and incubate the tubes in the dark for 15 minutes at the room.  
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Fig 3.5 F-actin rearrangement of macrophages exposed to membrane vesicle. Macrophages were 
prepared on 8 chambered cover glass by seeding 25000 cells /well on 8 chambered cover glass. Before 
treatment of MVs macrophage was serum starved for at least 20 hours after that Vesicle from control 
without treatment and ATCC29833 and YPIII (+) respectively imaged at 40X magnification. (b) 
macrophage stained with CMTPX red then treated with 10µg/ml of vesicle then incubated 48hour the 
cells were washed with DPBS and counter stained with DAPI then visualized Unde confocal 
microscope image were taken at a magnification of 10X. 
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Fig 3.6 Y. pseudotuberculosis membrane vesicle leads to morphological changes and 
multinucleation of macrophages.  80% confluent macrophages were prepared on  96 well plate by 
seeding 25000 cells /well. Before treatment macrophage was stained with CMPTX red then treated with 
10µg/ml of purified MVs from both ATCC29833 and YPIII (+) were treated after treatment cells were 
incubated for 48 hours. After 48 hours, unattached MVs were removed by washing with DPBS then 
subsequently fixed with 3.7% of paraformaldehyde  incubated 10 min and washed again with DPBS. 
Nucleus were counterstained with DAPI and visualized under a microscope (scale bar 20 µm). 
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Fig 3.6 Secretion of TNF-alfa by macrophages response to Y. pseudotuberculosis MVs. 
Macrophages cells were grown on 12-well plate  5X104 cells/well for 24 hours, and then replaced media 
with vesicle 10 µg/ml of MVs (5 µg/well) and incubated in a CO2 incubator at 37ºC for 24 hours. After 
24 hours, cell culture media were collected for ELISA. TNF-α concentration was quantified using 
ELISA kits from R&D Systems. 
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3.5 Conclusion  
In summary, the data presented in this study focused on the effect of Y. pseudotuberculosis 
membrane vesicle MVs on murine macrophage. Purified membrane vesicles were uptake by the 
macrophage. The MVs showed cytotoxicity and induced a higher level of the TNF-alfa, and cytotoxicity 
was not due to the apoptosis. Concluded that the cytotoxicity of the macrophages was due to various 
proteins associated with the membrane vesicle, and the MVs were shown to be phagocytized by the 
macrophage. It confirms the presence of the Yersinia cytotoxic necrotizing factor CNFy associated with 
MVs which leads to actin rearrangement and giant cell multinucleation.  We hypothesize the novel 
mechanism of delivery of  CNFy into macrophages by a Y. pseudotuberculosis though receptor for 
attachment or secretion system for CNFy not yet identified. 
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Chapter 4 
Analysis of Post Translational Modifications (PTMs) Yersinia 
pseudotuberculosis Cytotoxic Necrotizing Factor (CNFy) 
4.1 Summary   
Cytotoxic necrotizing factor toxin (CNF) is one of the crucial virulence factor allied with 
Yersinia pseudotuberculosis YPIII. CNFy plays a critical role in the delivery of virulence factor and 
survival in the host system. Our previous proteomics study we found that there was some signature of 
post translational modification (PTM) in CNFy protein. For further confirmation, we cloned the ORF 
of CNFy with its promoter into a pET31b+ vector with His-tag and expressed in both E.coli (ECNFy) 
and Yersinia pseudotuberculosis YPIII (YCNFy). Expressed protein were purified by affinity 
chromatography using Ni-NTA agarose and quantified by ELISA using HisProbe-HRP. Furthermore, 
1ug/ml each ECNFy and YCNFy were tested for their multinucleation activity on airways epithelial  
NuLi-1 cells,  result confirms YCNFy is 8 times more active compared to ECNFy. Furthermore purified 
protein were analyzed by mass spectrometry (LC-MS/MS) followed by post translational 
modification(PTM) analysis. Surprisingly there were 60 PTMs in the protein YCNFy, but ECNFy had  
6 modified amino acid. All  six modifications change are common in both YCNFy and ECNFy in that 
lysine 1003 is methylation one of the specialized PTM found in both protein.  There is 17 glutamic acid 
methylation found in YCNFy. 6 and 37 Dimidiated asparagine found ECNFy and YCNFy 
respectively.The result suggests that the activity CNFy is interrelated with the post translational 
modification. 
4.2 Introduction  
 Cyto toxic necrotizing  factor (CNF) is a pore-forming toxin that was first identified in E.coli 
107 it was later identified in other bacteria including Yersinia pseudotuberculosis70. Yersinia 
pseudotuberculosis cytotoxic necrotizing factor (CNFy) gene is encoded by an open reading frame of 
3,045bp and located on the chromosomal DNA. The amino acid sequence of CNF exhibits about 61% 
similarity with E. coli CNF1108. A recent report about host immune response confirmed that there was 
a reduction of phagocytosis in the presence of CNFy109. The absence of CNFy allows immune cells to 
rapid elimination of the pathogen. CNFy toxin leads to the formation of actin-rich membrane ruffles 
and filopodia110, and also helps to deliver type III effector into epithelial and immune cells in vitro also 
enhance the infection further demonstrated that CNF increases suppression of the antibacterial host 
response69. A Recent study identified the Lutheran (Lu) adhesion glycoprotein/basal cell adhesion 
molecule (BCAM) as a cellular receptor for CNF111. But the receptor for CNF has not been identified. 
After binding to its receptor, CNF enters endocytic vesicles by receptor-mediated endocytosis, which 
is independent of clathrin and sphingolipid-cholesterol-rich membrane micro domains (lipid rafts)112. 
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The activity of CNF is interesting. CNF has conserved C-terminal catalytic domain between 720 to 
1014 amino acid. C-terminal catalytic part of. Cysteine 866, and Histidine 881 have been found to be 
crucial for the catalytic activity of CNFy. This domain was conserved in the crystal structure, where the 
third residue of the catalytic triad, Valine 833, was identified113.  
CNF selectively activates RhoA GTPase compared to CNF1. Cell-free lysate supernatants and 
spent media of Y. pseudotuberculosis strains have been shown to contain the complete CNF protein and 
have induced the development of Hep-2 cells into a giant, multinucleated cells70. The activity of CNF 
is independent of the type III secretion system. The mutinlucealtion is mainly due to the RhoA GTPase 
activation as CNF catalyzes the deamidation of RhoA at Gln63. This is the one of the post-translational 
modifications that affect several downstream signaling events, unlike other bacterial toxins113. 
Cell signaling networks are information-processing circuits that control almost all cellular 
functions. Signalings are regulated by reversible protein post-translational modifications (PTMs)114 that 
allow cells to respond rapidly to internal and external cues. Hundreds of different PTMs have been 
identified. Controlling the spatial distribution of proteins is an important mechanism for regulating their 
function, and subcellular localization of many transcription factors is extensively regulated by PTMs115. 
Positively charged lysines are often found in the subcellular localization signaling domains of 
proteins116, and their acetylation can regulate the subcellular localization of the proteins109. 
PTM is the widespread strategy used by prokaryotes and eukaryotes to modify quickly, locally 
and specifically the activity of key factors and enable cells to respond rapidly to environmental 
changes117. The diversity of protein functions is generated by PTMs that alter the structure/function 
relationship and impact protein complex formation, enzyme catalysis and other biomolecule 
interactions118. Recently, the study of PTM in bacterial protein has demonstrated that prokaryotes are 
capable of modifying proteins with an extensive array of PTMs and that these have a profound influence 
on bacterial physiology and virulence119. 
Based on a previous study with proteomic analysis of Yersinia pseudotuberculosis membrane 
vesicles we found that some modification may found in the CNFy. The vesicle contains a large quantity 
of other protein and it was stiffer to confirm the PTM. This study demonstrated the difference in the 
activity of CNF expressed in E.coli (ECNFy), and Yersinia (YCNFy) , and PTM analysis of both 
proteins showed CNF expressed in Y. pseudotuberculosis (YCNFy) has specialized PTM compared to 
the ECNFy is significantly high in number, here we hypothesized that PTM is required for the activity 
the CNF protein. 
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Materials and method  
4.3.1Culture of human airway epithelial cell line (NuLi-1) 
Bronchial Epithelial NuLi-1(ATCC CLR 40110) cells cultured in T75 flasks in Bronchial 
Epithelial Cell Growth Medium (BEGM; Lonza USA) substituted with antibiotic (Normocin, 100 
µg/ml) until they were confluent. Cells were then washed with sterile DPBS and trypsinized until 
detached from the flask. Cells then washed with Complete media supplemented with FBS (ATCC, 
USA), counted and diluted appropriately to seed in an appropriate culture dish for the experiment. 
4.3.2 Cloning of CNFy ORF with promoter 
CNFy gene with promoter amplified by PCR from genomic DNA of Y. pseudotuberculosis 
strain YPIII using CNF-F 5′-GGATCCATGAAAAATCAATGGCAACATCAATATTT-3′ as sense 
primer andCNF R  5′-CCCGGGGATATCTTTTCATTTCCCCCTGCC-3′ as an antisense primer, 
thereby introducing restriction sites for restriction enzymes Xba1 and Xho1 The resulting PCR product 
was cloned into the expression vector pET31b+ and transformed into E. coli DH5α further the plasmid 
transformed into Yersinia YPIII strain.  
4.3.3 Expression and purification of His-tagged CNFy  
CNFy toxin purification,  Both E. coli Dh5α and, Y. pseudotuberculosis  YPIII carrying 
pET31b-CNF-His  grown in LB medium to reach OD 1.0  cells collected by centrifugation and resulted 
in the pellet were suspended in lysis buffer(50 mM Tris-HCl pH 7.5; 200 mM NaCl)  then supplemented 
with lysozyme 1mg/ml. Suspension kept in ice for 30 minutes before sonication then sonicated, 
sonicated suspension were centrifuged and purified by affinity chromatography on Ni-NTA agarose 
(Qiagen; USA).loaded beads were washed with lysis buffer (with 20mM imidazole) at 4 °C. The CNF-
His fusion proteins were eluted from the beads by glutathione (500mM imidazole with lysis buffer ) 
twice for 10 min at room temperature.  
4.3.4 Quantification of CNFy by ELISA  
 A standard curve for ELISA was made using CNFy expressed in Yersinia pseudotuberculosis 
by confirming their purity by SDS page.  Purified CNFy were coated on co-star plate using (Coating 
Buffer: 0.1M sodium bicarbonate buffer; pH 9.6) Incubated for two hours at room temperature then 
blocked by adding 200μL of blocking Buffer the buffer supplemented with skimmed 5% Milk to each 
well. Incubate for 30 minutes at 37°C. Washed plate three times with 200μL of wash buffer. Add 100μL 
of HisProbe-HRP dilutions. Working solution (1:5000 dilution in blocking buffer) to each well and 
incubate for 15 minutes at room temperature. Washed plate four times with 200μL of Wash Buffer. 
Added colour reagent A and B (R and D Systems, USA) incubated 30 min at room temperature then 
stop solution added and allow colour then measure absorbance at 450nm 
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4.3.5 Quantification of multinucleation 
To determine the multi-nucleation, 50% confluent monolayer of NuLi-1 cells prepared in 96 
well plates.prior to CNFy treatement cells were stained with CMPTX Red (life technologies, the USA). 
After staining different concentration of ECNFy and YCNFy treated to the stained cells and incubated 
for 48 hours in a CO2 incubator with 5% CO2 were stained with CMTPX red then incubated with the. 
After incubation cells were washed with DPBS ( Sigma-Aldrich, USA ) and fixed with 4.0 % of 
paraformaldehyde for 10 min at room temperature. Fixative were removed by washing three times with 
DPBS and by washing, and fixed cells were counterstained with DAPI. Then cells were visualized under 
the confocal microscope (LSM 700: Carl Zeiss, Germany) at the magnification 20X and images 
captured using Zen 2009 software.Multinucleated cells were visually counted and calculated percentage 
of multinucleated cells. 
4.3.6 MTT assay to assess cytotoxicity of ECNFy and YCNFy  
The toxic effects of purified CNFy in-vitro were analyzed by quantitatively determining cell 
viability of human airway epithelial cell (NuLi-1). In 96-well plate, 50% confluent airway epithelial 
(HAE) was prepared and treated with 2000 ng down to 20 ng of ECNFy and YCNFy in BGEM media 
and incubated for 48 hours in a CO2 incubator. Briefly, MTT solution (5 mg/ml) in BGEM media was 
added to each well in an amount equal to 10%. Cells were incubated for at least 2 hours at 37°C.after 
that the media were removed, and cells were lysed with DMSO (Sigma-Aldrich, USA) Absorbance was 
measured at a wavelength of 540 nm, and the percentage of viable cells was calculated as the ratio of 
absorbance of stained cells. 
 
4.3.7 Analysis of CNFy Proteins by LC-MS/MS 
SDS-PAGE gel electrophoresis analyzed purified CNF proteins. 5ug microgram CNFy 
from both preparation were suspended in loading buffer (62.5 mM Tris-HCl, pH 6.8, 4% SDS 
(w/v), 20% (v/v) glycerol and 0.001% bromophenol blue) and denatured by heating at 95 ºC 
for 5 min. Samples loaded onto a 10 % SDS-PAGE. After electrophoresis, the gels were washed 
with water then stained with colloidal Coomassie.   
 For tryptic peptides preparations (5 μg) were applied to 7.5 % Tris-glycine SDS-PAGE 
gel (Bio-Rad, USA). After staining with colloidal Coomassie, the each band separated into 6 
were subjected to in-gel tryptic digestion, as described by Shevchenko and co-workers 85. The 
resulting tryptic peptides were analyzed by LC-MS/MS. All mass analyzes were performed on 
an LTQ-Orbitrap (Thermo, Bremen, Germany) equipped with a nanoelectrospray ion source. 
To separate the peptide mixture, we used a C18 reverse phase HPLC column (150mm x 75um 
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i.d.) using an acetonitrile/0.1% formic acid gradient from 10 to 24% for 90min at a flow rate 
of 300 ml/min.  
For MS/MS analysis the precursor ion scan MS spectra (m/z 400–2000) were acquired in the 
Orbitrap at a resolution of 60,000 at m/z 400 with an internal lock mass. The 20 most intensive ions 
were isolated and fragmented in the linear ion trap by collisionally induced dissociation (CID).All 
MS/MS samples were analyzed using Sequest (Thermo Fisher Scientific, San Jose, CA, USA; version 
1.4.1.14) and X! Tandem (The GPM, thegpm.org; version CYCLONE (2010.12.01.1)). Sequest and X! 
Tandem were set up to search the Yersinia pseudotuberculosis YPIII CNFy (http://www.uniprot.org/))  
assuming the digestion enzyme trypsin. 
Sequest and X! Tandem were searched with a fragment ion mass tolerance of 0.60 Da and a parent ion 
tolerance of 10.0 PPM. Carbamidomethyl of cysteine was specified in Sequest and X! Tandem as a 
fixed modification. Deamidated of asparagine and glutamine, methyl of glutamic acid, lysine, glutamine 
and arginine, oxidation of methionine, acetyl of lysine, serine, threonine and the n-terminus and 
phosphor of serine, threonine and tyrosine were specified in Sequest and X! Tandem as variable 
modifications. Glu->pyro-Glu of the n-terminus, ammonia-loss of the n-terminus, gln->pyro-Glu of the 
n-terminus were specified in X! Tandem as variable modifications. 
Scaffold PTM (Proteome Software, Portland, Oregon, USA) was used to annotate PTM sites derived 
from MS/MS sequencing results obtained using Scaffold (version Scaffold_3.0). Using the site 
localization algorithm developed by Sean A et al120 Scaffold PTM re-analyzes Scaffold PTM re-
analyzes MS/MS spectra identified as modified peptides and calculates A score values and site 
localization probabilities to assess the level of confidence in each PTM localization. Scaffold PTM then 
combines localization probabilities for all peptides containing each identified PTM site to obtain the 
best-estimated probability that a PTM is present at that particular site. 
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4.4 Result and discussion 
4.4.1 CNFy expressed in Y. pseudotuberculosis and E.coli 
Initially, the CNFy was cloned into PET 31b+. To control the expression level, we used native promoter 
of CNFy. The promoter showed compatible in E. coli, but the expression level was very low. Further, 
CNFy was expressed in E. coli (ECNFy), and Yersinia pseudotuberculosis. (YCNFy)  Purified protein 
was analyzed in SDS-PAGE gel and stained with colloidal Coomassie and confirmed the expression of 
CNF with a clear band observed around 115 kDa in both hosts. The concentration was determined by 
ELISA using a His-probe HRP conjugate Kit. The concentration of ECNFy and YCNFy was 122ug/ml 
and 276ug/ml, respectively. The concentration variation was clearly visible in SDS page gel. (Fig 4.1a)  
4.4.2 Activity of CNFy expressed in Y. pseudotuberculosis YPIII (+) was higher compared E. coli. 
Various studies have shown that CNFy is one of the toxins that leads to multinucleation in a different 
type of cells108. In our previous study, complementation of CNFy in Yersinia pseudotuberculosis ATCC 
29833 showed multinucleation in NuLi-1 cells (Fig 4.2). For further confirmation, the purified CNF 
from both hosts were tested on human airway epithelial cells NuLi-1 cells. CNF from both preparations 
was quantified by ELISA, and prepared final concentration 1000ng/ml then diluted serially and used 
for the multiplication test. The result confirms YCNFy leads to the formation of more than 80% 
multinucleation and even 500ng/ml also showed same activity, suggesting that the concentration more 
than 500ng optimal concentration. But ECNFy showed much lower levels, around 12% of 
multinucleated cells observed after treatment. The result suggests that the protein is 8- to 10-fold less 
potent in triggering multinucleation compared to YCNFy (Fig 4.4 and 4.2). The result is acceptable 
because recombinant protein expressed in different hosts have different activity because of the unfolded 
or the confirmation of the protein will be compromised when shown in a different host121. 
4.4.3. CNFy is nontoxic to human airway epithelial cells 
To determine the adverse effect of CNF on human airway epithelial cells. The viability of airway 
epithelial cells after 48 hours of treatment with purified ECNFy and YCNFy was determined by MTT 
assay. CNF were treated with Different concentration to the 50% confluent cells assay treated with 
ECNF and YCNF to the airway epithelial cells 1000ng/ml to 10ng/ml The results confirm that both 
preparations of CNF were non-toxic to the airway epithelial cells (Fig 4.3). A previous study has shown 
that I.C.V injection of the entire CNF toxin causes no lethal effects in animals109. 
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Fig 4.1 The SDS-PAGE analysis of purified CNFy from both and Y. pseudotuberculosis YPIII 
(YCNF) E. coli (ECNF).  a) Y. pseudotuberculosis and E. coli grown LB media till optical density 
Reaches to 1.0 OD the bacteria were pelleted and lysed with lysis buffer and sonicated and using Ni-
NTA and purified protein visualized in SDS-PAGE b) Quantification multinucleation after treatment 
of known concentration of CNFy expressed in both hosts. 
 
Fig 4.2 Laser confocal image of multinucleated cells. For the quantification of multinucleation 
CMTPX Red stained NuLi-1 cells were treated with purified CNFy at different concentration and media 
without CNF as Control. After treatment cell’s nucleus were stained with DAPI and imaged under 
confocal microscope at the 20X magnification (Images represented with false colouring) 
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Fig 4.3 Effect of purified CNFy on NuLi-1 Cells. The viability of the NuLi-1 cells was determined 
by MTT assay after 48-hour post treatment of different concentration of ECNFy and YCNFy. 
 
Fig 4.4 Quantification of multinucleation in NuLi-1 cells caused due to purified CNFy treatment. 
The viability of the NuLi-1 cells was determined after 48-hour post treatment of different concentration 
of E CNFy and YCNFy. 
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4.4.4 PTM analysis revealed high level of post translational modification in YCNFy 
Mass spectrometry analysis of CNFy protein showed there is a diverse post translational 
modification (PTM) present in the CNF expressed in both (Fig 4.5) Y. pseudotuberculosis YCNFy and 
E.coli ECNFy. Compared to YCNFy 60 modifications, ECNFy has only six modification. Out of 6 
modification lysine, 1003 is common modification found in ECNFy and YCNFy (Table 4.1). Over all 
YCNFy has diverse post translational modification total of 60 deaminations of the asparagine is one of 
the dominant modification present in both YCNFy and ECNFy has the highest modification. (Table 
4.2) methylation of glutamic acid is the second higest post translational modification present in the 
YCNFy, but it was absent in the ECNFy. 
4.4.5 Lysine (K) and glutamic acid (E) methylation in CNFy  
Lysine methylation is well characterized. In histone protein, it regulates the function of histone. 
Methylation is the addition of a methyl group into the amino acid, and the amino acid will have a change 
in its mass of 14 Da. Methylation of lysine residues in histones in DNA is the main regulator of 
chromatin structure and transcriptional activity in eukaryotic systems.  It depends on some addition and 
methylation can also be subdivided into two functionally different forms.  i) N-methylation of 
Lys/Arg/Gln, and ii) N-methylation involves the transfer of either one, two or three methyl groups onto 
the terminal amine (the number being dependent largely on the residue; the primary amine of Lysine 
can accept up to three methyl groups122. 
 In our study YCNFy has multiple methylations in amino acid 613 and 1003, but the ECNF has 
methylation in the 1003 amino acid only. Lysine methylation was previously detected in bacteria 
detected in L. interrogans identified 64 lysine-methylated sites from 58 proteins123. Methylation is due 
to the enzymatic reaction by methyltransferases. Previous report some methyltransferase enzyme from 
Rickettsia although could methylate it’s at multiple sites catalysed tri-methylation, while mono-, di- and 
tri-methylation124. In Yersinia, vagH methyl transferase is necessary for the in vivo survival of Y. 
pseudotuberculosis125. Also, two more methyl transferases protein related to pathogenicity and they are 
critical for disease progression. Lysine methylation also plays a role in receptor-mediated signal 
transduction125.  
  In this study, we found that methylation of glutamic acid is the second largest type of PTM. 
There are 27 glutamic acids methylated amino acid found in YCNFy. Interestingly it was not detected 
in ECNFy. Previous studies have reported glutamic acid modification in E.coli protein, and it has been 
shown to modulate chemotactic responses in E.coli126. It was hypothesized that methylation of glutamic 
acid plays a key role in protein folding and functions; it is expected that neutralization of the amino 
acids, negative charge would have a significant impact on the proteins127 
 
72 
 
 
 
 
 
 
 
Fig 4.5 various post translational modification (PTMs) present in CNFy expressed in Y. 
pseudotuberculosis YPIII (+) 
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2 1
1
1
1
37
Methylation  Glutamic acid
Methylation  lysine
Methylation  glutamine
Acetylation  lysine
Acetylation  threionine
Acetylation  Asparagine
Deamidation  Asparagine
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4.4.6 Acetylation found only in YCNFy, not in ECNFy   
Acetylation is one of the prominent PTM in bacterial protein. Protein N-acetylation is the addition of 
an acetyl group to either the ε-amines of Lys side chains (Nε-acetylation) or the α-amines of protein N-
termini (Nα-acetylation) and it was first identified in eukaryotic histones. In our study, we found 
acetylation of lysine, threonine, and asparagine was found in only YCNFy (Table 4.2). Lysine 
acetylation is linked with acetyl-coenzyme a metabolism also cellular signaling128. Recent research has 
highlighted the mechanisms by which acetylation regulates various cellular processes.109 Lysine is one 
of the most frequently modified amino acids, and it can accommodate several types of acylation. 
Acetylation also leads to subcellular localisation some of the protein in eukaryotes129. Lysis acetylation 
may help the CNFy to localize in the cells with their interaction partner. 
4.4.7 Deamidation of asparagine (N) 
Deamidation of the asparagine was found to be most abundant PTM in YCNFy total of 37 amino acids 
were deamidated it is more than 50% PTMs in YCNFy.  Deamidation of asparagine is also associated 
with ECNFy, but it is a relatively low number (Table 4.2) Deamidation is the critical protein post-
translational modifications that contribute leads to various disease celiac disease, urinary tract infection, 
cataract formation, cancer, Alzheimer's130. Deamidation also effects the therapeutic protein purity and 
shelf life. It is the one of the known non enzymatic modification  it occurs in both occur both in vivo 
and in vitro131  
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Table 4.1 Post translational modification commonly present with CNFy expressed in Y. 
pseudotuberculosis YPIII  and E. coli   
  
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.2 Post translational modification (PTMs) Modification found in different amino acid  
 
 
 
 
 
 
 
 
 
 
 
Serial No Amino acid Modification  
1 N149 Deamidated 
2 N451 Deamidated 
3 N611 Deamidated 
4 N988 Deamidated 
5 N1000 Deamidated 
6 K1003 methyl 
Modification  Amino acid  YCNFy ECNFy 
Methylation  Glutamic acid  17 0 
 Lysine 2 1 
 Glutamine  1 0 
Acetylation  Lysine  1 0 
 Threonine  1 0 
 Asparagine  1 0 
Deamidation  Asparagine  37 5 
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 Fig 4.6.Protein sequence data obtained from the Scaffold PTM showing the presence of PTM 
CNF expressed in E. coli (ECNFy), and Y.pseudotuberculosis (YCNFy). ECNFy has much lover 
modification compared to YCNFy.  
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4.5 Conclusion  
Post translational modification (PTM) occurred in cytotoxic necrotizing factor (CNFy); CNFy 
expressed in Y. pseudotuberculosis shown a significantly higher rate of Post translational modification 
compared to CNFy expressed in E. coli. Based on previous reports post translational modification are 
play a key role in cells signaling during pathogenesis and disease progression, Methylation of lysine 
(K), glutamic acid( E) and deamination of asparagine(N)  and lysine (K) acetylation are characterized 
in the context of cells signaling or disease progression. In our study CNFy is one of the major virulence 
factors that causes very precise signaling event during interaction with the host system. It is clearly 
confirmed CNFy expressed in E. coli is less active compared to the YCNFy. So here we hypothesize 
post translational modification is probable players in the activity of CNFy. Further research should be 
focused on identification for essential PTM for the activity and identification of enzyme required for 
the modification in Y. pseudotuberculosis.  
 
 
Fig 4.7 Hypothetical model showing YCNFy leads higher level of giant cell multinucleation 
compared to ECNFy.  
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Chapter 5 
Conclusion 
 
Chapter 2 discussed the production and characterization of Yersinia pseudotuberculosis 
membrane vesicles (MVs) and MV-associated vesicular proteins including various virulence factors. 
Purified MVs induced morphological changes in human airways epithelial cells NuLi1 and were shown 
to be cytotoxic when they were internalized by human host cells. MVs delivered cytotoxic necrotizing 
factor (CNFy) and chaperonin-60 kDa inside NuLi1 cells.  
Chapter 3 was more focused on the response of immune cells. The study was continued to the 
direction of what could be the response on murine macrophages RAW 264.7 cells. Purified MVs from 
CFP expressing ATCC 29833 and YPIII (+) strains were used to treat murine macrophages until 48 
hours. There was a significant loss in viability due to MVs treatment with viability reducing down to 
around 50%. Also giant cell multinucleated phenotype were observed after exposure to MVs. A Higher 
level of TNF-α from Raw cells were induced after 24 hours of exposure to MVs from both ATCC and 
YPIII strain (≥5.2 ng/ml). Further study confirmed there was no significant apoptotic population among 
the MV treated raw cells. This suggested that apoptosis was not a major event in MV mediated 
cytotoxicity in mouse macrophage cells.  
Chapter 4 we focused on characterizing Cytotoxic necrotizing factor toxin (CNFy), which is 
one of the major virulence factor associated with Yersinia pseudotuberculosis YPIII. CNFy plays a 
crucial role in delivery of virulence factor and survival in host system. In our initial proteomics study 
we found signature Post translational modification of the Yersinia pseudotuberculosis CNFy protein. 
For further confirmation, CNFy was expressed in E.coli and YPIII strains and purified CNFy were 
quantified using ELISA using His probe HRP conjugate. 1ug/ml of purified CNFy was tested for multi-
nucleation in NuLi1 cells. Results suggested that CNFy expressed in Yersinia pseudotuberculosis YPIII 
(+) has 10 times more activity than CNFy expressed in E.coli. And when the purified protein was further 
subjected to post translational modification (PTM) analysis using mass spectrometry, we surprisingly 
found 60 Post translational modifications in the protein expressed in Yersinia pseudotuberculosis YPIII 
while PTM in E. coli CNFy revealed only 6 amino acid modifications. Out of these six modifications, 
methylation in Lysine 1003 was found common in both Yersinia and E.coli. In contrast, 17 glutamic 
acid methylations could be detected in CNF expressed in Yersinia pseudotuberculosis only. 
Future prospective  
This study lay down a foundation for the application of membrane vesicles: a potential 
candidate for the acellular vaccine. Yersinia is known to be one of the candidates for killed 
vaccine.Yersiniavax® is the one whole cell killed vaccine that made use of inactivated Yersinia 
pseudotuberculosis and is used for the immunization of wild deer. In our study, we found that 60 kDa 
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Chaperonin  is the most abundant and constantly concentrating protein associated with membrane 
vesicle. It is one of the pathogenesis-related protein in most of the pathogens. Chaperonin 60 proteins 
directly activate cells that lead to the inflammatory response. Chaperonin is on of the candidate for the 
subunit vaccine.These properties were explored in B.pertusis subunit vaccine made from the bacterial 
chaperonin 60 proteins. Furthermore, the recombinant chaperonin also concentrated in the In E. coli. 
So, further study should be targeting chaperonin to control the Yersinia infection. 
Bacterial toxins play an important role in infection and disease pathology. At the same time, 
some toxins can serve as potential candidates for therapeutics due to their immune inducing property. 
CNF1 from E. coli has already been under consideration for this scheme. In vivo Studies revealed that 
intravenous injection CNF1 was not lethal for mice, but its in vivo application was difficult due to high 
molecular weight (114kDa). In our study we showed that CNFy from Yersinia Pseudotuberculosis was 
65% similar to CNF1 and particularly activated RhoA showing same activity and having a lower 
molecular weight. So we propose and expect to elaborate our study relating CNFy to explore its alleged 
therapeutic potential. Altogether Chaperonin 60 and CNFy from Y. Pseudotuberculosis offers an 
intriguing clue for future vaccination and therapeutic strategy. This can open up the scope of new 
research in future.  
 
 
 
 
 
 
 
 
Fig 5.1 Yersinia pseudotuberculosis membrane vesicle interact with different host cells and series of 
response from the host. 
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APPENDIX -1 Representative mass spectrum of glutamic acid (E) Methylation and Lysine(K) 
Methylation    
 
 
1) Glutamic acid methylation (E 605 ) in cytotoxic necrotising factor 
 
 
 
2) Lysine methylated peptide (K 1003) methylated in both YCNFy and ECNFy   
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